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This work describes the development of methods to access synthetically 
useful chiral diols in enantiomerically pure form. First chapter describes the 
development of a stereodivergent approach for enantioenriched synthesis of 2-
cyclopentene-1,3-diol that was later converted to 4-hydroxy-2-cyclopentenones (4-
HCPs), which are highly privileged synthetic building blocks with numerous 
applications in natural product syntheses and pharmaceuticals. The present approach 
enables the gram scale synthesis of 4-HCPs with chemically diverse protecting 
groups, in a stereodivergent manner. In chapter 2, we describe the development of a 
unified strategy for the stereodivergent synthesis of enantioenriched 1,3-dihydroxy 
substituted six-membered carbo- and heterocyclic rings. The previously known 
approaches for accessing these compounds involve multiple synthetic steps and one 
or more enzymatic steps. We developed a purely synthetic approach to synthesize 
enantioenriched carbo- and heterocyclic six-membered 1,3-diols from a common, 
highly economical commercial available starting material. In Chapter 3, we described 
the development of a small-molecule library of stereochemically diverse compounds 















To my father 























First and foremost, I would first like to thank my advisor Professor Jeff Aubé 
for his excellent mentorship and tremendous support during my time at KU. His 
continual guidance and constant encouragement kept me engaged with my research. I 
thank you for teaching me not to give up under any circumstances and believing in 
me.  I am very grateful for all that you have done for me.   
I also extend my deepest regards and thanks to the honorable committee 
members Professors Helena Malinakova, Paul Hanson, Michael Rafferty and Apurba 
Dutta to serve on my dissertation committee, and for their useful suggestions.  
I extend my appreciation and thanks to all my laboratory colleagues in Aubé 
group. Especially, I am indebted to Drs Digamber Rane and Sarah Scary for their 
support on several occasions for providing useful insights on my research documents. 
I also wish to thank former postdoc colleagues in Aubé group, Drs Chan W. Hu and 
Tom Coombs for their valuable research insights and suggestions. I would also like to 
thank former and present graduate students in Aubé group, especially Ruzhang, 
Hashim, Rakesh, Huiyong and Manwika for being great colleagues and friends.  
I would also like to extend my appreciation and thanks to Patrick, Ben and 
David for their support in my library projects. I also thank Justin and Sarah for the 
NMR support. I would like to acknowledge Shelley Sandberg and Cady Bush for the 
administrative support and organizing many funful events for the group. I would also 
like to thank the staff of the Medicinal Chemistry office, Norma and Jane for their 
support during my time at KU.  
 vi 
It would have never been possible to reach this goal without the support of my 
family and friends. I deeply acknowledge and thank my wife, Dr. Soma Maitra, for 
her unconditional support and love.  I am thankful to my mother for being very strong 
and taking huge responsibilities back home when I was not able to be there for all 
these years. I personally thank my best friends Raman and Rajesh, and my younger 
brother Harpreet for being there to support my family in India, on a number of 








CONTENTS             Page # 
Title Page              i 
Acceptance Page            ii 
Abstract             iii 
Acknowledgments             iv 
Table of Contents           vii 
List of Figures             ix 
List of Tables              x 
List of Schemes            xi 
Abbreviations                      xvi 
 
Chapter 1: Synthesis of enantioenriched 4-hydroxy-2-cyclopentenones     
1.1 Introduction            1 
1.2 HCPs as important synthetic intermediates for prostaglandin synthesis     2      
 1.2.1 A brief introduction to prostaglandins        2                   
 1.2.2 Emergence of 4-HCPs as potential chiral building blocks for the  
          synthesis of prostaglandins         2 
1.3 Synthetic approaches for the synthesis of 4-hydroxy-2-cyclopentenones  
1.3.1 4-HCP synthesis by enzymatic hydrolysis or acylation of 
cyclopentenoids          5 
1.3.2 Synthesis from D-tartaric acid                   9 
1.3.3 Non-enzymatic desymmetrization or kinetic resolution                         11 
1.4 Synthetic applications of 4-HCPs         13 
1.4.1 Synthetic approaches to prostaglandins from 4-HCPs 
  1.4.2 Application of 4-HCPs in non-PG natural product synthesis 
1.5 Results and Discussion         19 
           1.5.1 Synthesis of (3R,5R)-hepta-1,6-diene-3,5-diol                  22 
           1.5.2 Synthesis of mono-protected diols                   24 
 viii 
           1.5.3 Synthesis of cyclopentene diol and enones                  26 
           1.5.4 Derivatives of HCP                     28 
 
Chapter 2: Development of a stereodivergent approach toward the synthesis of 
3,5-disubstituted six-membered carbo- and heterocyclic rings  
  
2.1 Introduction          32 
2.2 Synthesis and applications of cyclohexane-1,3-diols     33 
2.3 Synthesis and applications of 3,5-dihydroxy piperidines    41 
2.4 Results and discussion         44 
 
Chapter 3: Development of libraries based on 5- and 6-membered cyclic diols 
   
 3.1 Introduction           55 
 3.2 Diversity-oriented synthesis (DOS) based on natural products     56 
 3.3 Design strategies for DOS of natural product-like libraries    57 
3.3.1 Libraries based on core scaffolds of natural products                57    
3.3.2 Libraries based on common substructures from classes of natural   
products           59 
3.3.3 Libraries with general structural characteristics of natural products   59
                 
3.3 Small-molecule libraries of stereochemically diverse compounds    62 
3.4 Results and discussion          64 
 3.4.1 Synthesis of starting materials        65 
 3.4.2 Optimization of library method       66 
 3.4.3 Library synthesis         66 
 3.4.4 Library of C2-symmetric biscarbamates      75 
         
Chapter 4: Experimental          79 




List of Figures 
 
Figure 1.1 Natural products containing 4-hydroxycyclopentenone motif 1 
Figure 1.2 Prostaglandin natural products 2 
Figure 1.3 Corey’s approach for the synthesis of PGE2 3 
Figure 1.4 Stereochemical analysis of the enzymatic route 23 
Figure 2.1 Examples of natural product structures containing a 1,3-
cyclohexanediol or 3,5-dihydroxy piperidine motif 
 
35 
Figure 2.2 Synthetic compounds of therapeutic importance containing six-
membered carbo- or heterocyclic-1,3-diol motif 
 
36 




Figure 3.2 Dysidiolide inspired library of butenolide derivatives 65 
Figure 3.3 Library of spirooxindoles based on spirotryprostatin B 65 
Figure 3.4 Library comprising 2,2-dimethylbenzopyrans as structural motif 66 
Figure 3.5 Inhibitors identified from Schreiber’s dioxane based library 68 
Figure 3.6 Protein-protein interaction inhibitors from a peptide-like library 69 
Figure 3.7 Conformationally diverse lactones 70 
 x 
Figure 3.8 Examples from Ellman’s library of spatially separated compounds 
determining cathepsin D inhibitory activity 
 
69 
Figure 3.9 Stereodiversified library of enediols from Verdine’s group 70 
Figure 3.10 Integrating prostaglandin core with amino acids 71 
Figure 3.11 Library plan 73 




List of Tables 
 
Table 2.1 Optimization of conditions for the synthesis of  
3,5-dihydroxy piperidines 
58 
Table 2.2 Optimization of the thiopyran ring formation 59 














Scheme Title Page 
Scheme 1.1 Sih’s two-component approach to PGs 4 
Scheme 1.2 Sih’s approach to asymmetric synthesis of prostaglandins 5 
Scheme 1.3 Baker’s yeast hydrolysis of 3,5-diacetoxy-1-cyclopentene 
 
6 









Scheme 1.6 Synthesis of meso-2-cyclopentene-1,4-diacetate 
 
8 
Scheme 1.7 Paquette’s route for the synthesis of (R)- and (S)- HCPs 9 
Scheme 1.8 Myers’s route for the synthesis of HCP 10 
Scheme 1.9 Synthesis of enantioenriched 4-HCPs from L-tartaric acid 
 
11 
Scheme 1.10 Noyori’s BINAL-H reduction of 1,3-diketones 11 
Scheme 1.11 Pd-catalyzed synthesis of 4-HCPs using Trost ligand 12 
 xii 
Scheme 1.12 Catalytic opening of meso-epoxides 14 
Scheme 1.13 Noyori’s three component synthesis of PGs 15 
 
Scheme 1.14 Danishefsky’s synthesis of PGs 
 
16 
Scheme 1.15 Suzuki’s route to PGs 16 
Scheme 1.16 Corey’s synthesis of (+)-pentacycloanammoxic acid 
 
18 




Scheme 1.18 Overman’s synthesis of spongian diterpenes 
 
20 
Scheme 1.19 Total synthesis of arglabin 
 
21 
Scheme 1.20 Synthesis of (R)-4-hydroxy-2-cyclopentenone by Angelica 
Meyer 
24 
Scheme 1.21 Preparation of (2R, 4R)-1,5-dichloro-2,4-pentanediol 
 
25 
Scheme 1.22 Synthesis of (3R,5R)-hepta-1,6-diene-3,5-diol 
 
26 
Scheme 1.23 Monosilylation of (3R,5R)-diol    27 
Scheme 1.24 Mono acylation of (3R,5R)-diol 1.20.1 
 
28 




Scheme 1.26 Synthesis of cyclopentenols via ring-closing methathesis (RCM) 
 
29 
Scheme 1.27 Synthesis of 4(R)-O-protected-hydroxycyclopentenones 
 
30 
Scheme 1.28 Synthesis of (S)-4-O-TIPS-cyclopentenone 
 
30 
Scheme 1.29 Iodination of enone 1.20.4 31 




Scheme 1.31 Cycopentene derivatives via Mitsunobu displacement  32 
 Chapter 2 
 
 




Scheme 2.2 Suemune’s synthesis of enantioenriched cis and trans-
cyclohexene-1,3-diols  
39 
Scheme 2.3 Applications of cyclohexanediols toward 
 
40 
Scheme 2.4 Sweeney’s approach toward the synthesis of 1,3-
cyclohexanediol 
42 
Scheme 2.5 Kalkote’s approach toward the synthesis of enantioenriched 
3,5-dihydroxy cyclohexanone  
43 




Scheme 2.7 Cossy’s ring-expansion approach towards enantioenriched 3,5-
dihydroxy piperidines  
45 
 xiv 
Scheme 2.8 Bäckvall’s synthesis of racemic 3,5-dihydroxy piperidines 
 
46 
Scheme 2.9 Bäckvall’s chemoenzymatic approach toward the synthesis of 
enantioenriched 3,5-dihydroxy piperidines  
47 
Scheme 2.10 Schreiber’s synthesis of talaromycin B 
 
49 




Scheme 2.12 Linclau’s approach to carabanucleosides 51 
Scheme 2.13 Our design rationale for the synthesis of cyclohexane-1,3-diols 52 
Scheme 2.14 Synthesis of the epoxide substrate  53 
Scheme 2.15 Synthesis of 1,3-cyclohexanediol  
 
55 
Scheme 2.16 Deprotection of dithiane 
 
56 
Scheme 2.17 Synthesis of (1S,3S)-cyclohexane-1,3-diol 56 
Scheme 2.18 Synthesis of (3R,5R)-1-benzylpiperidine-3,5-diol 
 
57 
Scheme 2.19 Synthesis of (3S,5S)-1-benzylpiperidine-3,5-diol  58 
Scheme 2.20 Synthesis of (R,R)-3,5-dihydroxy tetrahydrothiopyran 59 




 Chapter 3  
 
Scheme 3.1 Synthesis of dichlorodione  74 
Scheme 3.2 Synthesis of dichlorodiols 
 
74 
Scheme 3.3 Synthesis of diols (R,R)-1.25.1 and (S,R)-1.25.1 
 
75 
Scheme 3.4 Synthesis of diols (S,S)-1.25.1 and (R,S)-1.25.1 75 
Scheme 3.5 Synthesis of alcohol carbonate 76 
Scheme 3.6 Synthesis of carbonates 3.5.2 
 
76 
Scheme 3.7 Synthesis of silyl monocarbamates  
 
77 
Scheme 3.8 Optimization of method for biscarbamate synthesis 
 
78 
Scheme 3.9 Synthesis of (S,R,R,S)-biscarbamate library  79 
Scheme 3.10 Synthesis of (S,S)-cyclohexane-1,3-diol 
 
83 
Scheme 3.11 Synthesis of heterocyclic diols  
 
83 
Scheme 3.12 Synthesis of (S,S)-2-cyclopentene-1,3-diol 
 
84 





aq   aqueous 
Ac2O   acetic anhydride 
BnBr   benzyl bromide 
Boc   tert-butyloxycarbonyl  
nBuLi    n-butyllithium 
tBu   tert-butyl 
CALB   candida antarctica lipase B 
CHCl3   chloroform 
CH2Cl2  dichloromethane  
CSA   camphorsulfonic acid 
DEAD   diethyl azodicarboxylate 
DMSO   dimethyl sulfoxide  
DMAP   4-dimethylaminopyridine  
DIPEA  N,N'-Diisopropylethylamine 
DMF   dimethylformamide 
DOS   diversity oriented synthesis 
Et2O   diethyl ether 
equiv   equivalent 
Et   ethyl 
EtOAc   ethyl acetate 
ee   enantiomeric excess 
er   enantiomeric ratio 
Et3N    triethylamine  
HCl   hydrochloric acid 
HPLC    high performance liquid chromatography 
HMPA   hexamethylphosphoramide 
Hz    hertz 
 xvii 
IR   infrared radiation 
iPr   isopropyl 
K2CO3   potassium carbonate 
LiAlH4   lithium aluminum hydride  
MeCN   acetonitrile  
MeOH   methanol 
MsCl    methanesulfonyl chloride 
mesylation  methanesulfonation 
NMR   nuclear magnetic resonance 
NaHCO3  sodium bicarbonate 
PCC   pyridinium chlorochromate 
PMB    para-methoxybenzyl 
PPTS    pyridinium p-toluenesulfonate  
PPh3   triphenylphosphine 
PS-C   pseudomonas cepacia lipase 
PTSA   p-toluenesulfonic Acid 
RCM    ring-closing metathesis  
rt   room temperature 
SM   starting material 
TBAF   tetrabutylammonium fluoride 
TBS    tert-butyldimethylsilyl 
TBSCl   tert-butyldimethylsilyl chloride  
THF   tetrahydrofuran 
TIPS   triisopropylsilyl  
TIPSCl  triisopropylsilyl chloride  







Synthesis of Enantioenriched 4-Hydroxy-2-Cyclopentenones 
 
1.1 Introduction to 4-hydroxy-2-cyclopentenones (4-HCPs) 
Hydroxylated cyclopentanones and cyclopentenones are common motifs in a variety of 
natural product structures including prostaglandins (e.g. PGE2), antibiotics pentenomycin 
and viridinomycin, the antitumor dienediyne natural product N1999A2, terpenes 
hymenolin and numerous others (Figure 1.1). In addition, the tremendous reactivity 
potential of the 4-HCPs that was earlier recognized in the prostaglandin chemistry, has 
been exploited over last several years in complex natural product syntheses.1,2 
 
 























































1.2. 4-HCPs as important synthetic intermediates for prostaglandin synthesis 
1.2.1. A brief introduction to prostaglandins 
 The prostaglandins (PGs) are a group of physiologically active lipid compounds 
derived enzymatically from fatty acids. Biosynthetically, prostaglandins are derived from 
arachidonic acid and are transformed by prostaglandin synthetase into a number of 
structurally related carbocyclic molecules. They were discovered in the early 1930s by 
von Euler and by the mid-1960s the structures of the first family of prostaglandins were 
reported by Bergstrom et al. Structurally these contain 20 carbon atoms including a 5-
carbon ring and have 4 (1.2a, PGE2) or 5 (1.2b, PGF2α and 1.2c, PGI2) stereogenic centers 
of which 3 or 4 are the contiguous stereocenters in the cyclopentane ring (Figure 1.2). 
PGs have been found in almost every tissue in humans and other animals, and are 
responsible for the control of a number of essential biological processes including sleep, 
pain, fever, inflammation, menstruation, birth, and constriction of blood vessels and 
blood3 clotting.  
 
 
Figure 1.2. Prostaglandin natural products 
 





















 Because of their biological importance and structural complexity, the 
prostaglandins had been very important targets for synthesis both in academia and 
pharmaceutical industry.2,4 Various research groups including Woodward5, Corey6, 
Stork7, Noyori8, Danishefsky9 and others contributed significantly by developing 
innovative chemical methodologies for PG synthesis. In 1969, Corey’s group reported an 
elegant route (Figure 1.3) for the synthesis of PGE2 via a bicyclic lactone intermediate 
(1.3a) in which all the stereocenters were installed in the correct relative stereochemistry 
as in the original natural product structure.6 The lactone (1.3a) was obtained via a Diels-
Alder reaction of 2-substituted cyclopentadiene (1.3b) and 1-chloroacrylonitrile (1.3c) 
followed by Bayer-Villiger oxidation and iodolactonization.  
 
 
Figure 1.3. Corey’s approach for the synthesis of PGE2 
 
 Though the Corey lactone approach contained all but one stereocenter in the 
prostaglandin structure, its application to asymmetric synthesis of prostaglandins would 
require an enantioselective version of Diels-Alder reaction that was yet to be developed 
at that time. Contemporary to this work, several groups pursued research to develop 
alternative strategies for the synthesis of prostaglandin. Two publications from Sih’s 
group brought the attention of chemists to 4-substituted cyclopentenones as the potential 
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that C-4 substituent of the 4-hydroxy-2-cyclopentenone (1.1.1) could be used to direct the 
stereochemistry at both α- and β-carbons through conjugate addition of organocuprates.10 
It was an important result as it revealed that a single stereogenic center on the 
cyclopentenone ring could be used to install the remaining substituents in the desired 
stereochemistry required for the prostaglandin synthesis.  
 
 
Scheme 1.1. Sih’s two-component approach to PGs 
 
 Sih’s group also reported the synthesis of an enantiomerically pure 2-substituted-
4(R)-hydroxycyclopent-2-en-1-one 1.2.3 through microbial reduction of 2-substituted 
cyclopentanetrione 1.2.1 (Scheme 1.2).10 Reduction of the carbonyl group in 1.2.2 with 




Scheme 1.2. Sih’s approach to asymmetric synthesis of prostaglandins  
 





























alkylation prompted the researchers to develop efficient approaches for the synthesis of 
enantioenriched 4-hydroxycyclopent-2-en-1-one.2,4 A number of methods to synthesize 
enantioenriched 4-hydroxy-cyclopentenones have been reported since then. Following 
section highlights the conceptually unique and/or highly utilized strategies employed for 
the synthesis of enantioenriched 4-HCPs. 
 
1.3. Synthetic approaches for the synthesis of 4-hydroxy-2-cyclopentenones  
 
1.3.1. 4-HCP synthesis by enzymatic hydrolysis or acylation of cyclopentenoids  
 Kurozumi’s group was the first one to report the synthesis of both R and S 
isomers of 4-O-silyl-protected hydroxycyclopentenone.11 They performed the hydrolysis 
of a 1:1 cis/trans mixture of the racemic 2-cyclopentene-1,4-diacetate, 1.3.1, with baker’s 
yeast (Scheme 1.3).11 Depending upon the difference in the rate of enzymatic hydrolysis 
between different isomers of 1.3.1 the reaction resulted in a net accumulation of the 




Scheme 1.3. Baker’s yeast hydrolysis of 3,5-diacetoxy-1-cyclopentene 
 
 
 The trans-monoacetate (R)-1.3.3 was converted into 4(R)-tert-butyldimethyl-
siloxycyclopent-2-en-1-one (R)-1.4.3, by two different paths (Scheme 1.4). In the first 
route, the alcohol 1.3.3 was oxidized with manganese dioxide followed by hydrolysis of 
















Protection of the hydroxyl group at the next step with tert-butyldimethylchlorosilane 
gave the silylether (R)-1.4.3 in 90% ee. The alternative pathway at first involved 
silylation of the alcohol 1.3.3 to give silyl ether 1.4.4. Followed by reduction of the 
acetate group with LAH gave the alcohol (R)-1.4.5 that was oxidized with manganese 
dioxide to obtain the enone (R)-1.4.3. Though the latter route gave the higher overall 
yield of (R)-1.4.3, the enantiopurity of the product was inferior than the purity of the 





Scheme 1.4. Kurozumi’s synthesis of enantioenriched 4-HCPs 
 
 
 The enzymatic desymmetrization of the meso-cyclopentenoids has been a very 
effective method for the synthesis of enantioenriched 4-HCPs. The enantioselectivity of 
the enzymatic desymmetrization of meso-diacetate depends on the lipase used. Two 
reports have been highly cited in literature for procuring enantiopure 4-HCPs.12,13 In 
1986, Deardorff’s group reported the synthesis of mono acetate (1R, 4S)-1.3.3 by using 
Electric eel acetylcholinestrase in very good yield and excellent ee.12 The enantiomeric 






























Johnson and coworkers reported Novo SP-435 mediated monoacylation of the meso diol 





      Scheme 1.5. Enzymatic desymmetrization 
                                                 of meso-cyclopentene-1,4-diacetate 
 
 
 The ease of synthesis of the starting meso-diacetate further supports the utility of 
these enzymatic approaches. Furthermore, meso-1,4-diacetoxy-2-cyclopentene can be 
easily obtained from cyclopentadiene either via a tandem photooxygenation/reduction 
protocol, or via 3,4-epoxycyclopentene, subjected to palladium(0)-catalyzed allylic 





Scheme 1.6. Synthesis of meso-2-cyclopentene-1,4-diacetate 
 
 Considering the broad synthetic utility of silyl protecting group over the acetate, a 
AcO
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number of routes have been reported to obtain 4-tert-butyldimethylsilyloxy-2-
cyclopentenone. Paquette et al. reported the synthesis of both S and R isomers of 4-O-
tert-butyldimethylsilyloxy-cyclopentenones (Scheme 1.7).15 TBS protection of (1R,4S)-
1.3.3 provided (1R,4S)-1.4.4 in 77% yield. Hydrolysis of the acetate using sodium 
methoxide led to monosilylated diol (S)-1.4.5, which was subjected to oxidation with 
MnO2 to obtain enone (S)-1.4.3 in 87% over two steps. To synthesize the (R)-isomer, 
(1R,4S)-1.3.3  was oxidized to obtain acylated enone (R)-1.4.1. Treatment of (R)-1.4.1 
with wheat germ lipase for ten days provided the hydroxy-enone (R)-1.4.2 that on O-
protection with TBSCl provided (R)-1.4.3 in 32% overall yield. 
 
 
Scheme 1.7. Paquette’s route for the synthesis of (R)- and (S)- HCPs 1.4.3 
 
 Myers’s group reported an alternative to the slow enzymatic hydrolysis in the 
Paquette’s route (Scheme 1.8).16 They reported a route by introducing pivolyl-protected 
diol intermediate (R,S)-1.8.1, which was subjected to TBS protection followed by 
DIBAL-H mediated removal of the pivolyl protecting group to obtain monosilylated diol 
(R,S)-1.4.5. Finally subjecting alcohol 1.4.5 to PCC oxidation provided enone (R)-1.4.3 































Scheme 1.8. Myers’s route for the synthesis of HCP (R)-1.4.3 
 
 
1.3.2. Synthesis from D-tartaric acid  
 In 1976, Ogura reported the synthesis of both (R)- and (S)-4-hydroxy 
cyclopentenone from D- and L-tartaric acids respectively, in seven steps in 85% ee.17 In 
1995, Rokach and coworkers reported an improved version of this approach for large 
scale synthesis of (S)-4-hydroxy cyclopentenone by utilizing acidic Amberlyst resin at a 
later stage in the synthesis (Scheme 1.9).18  Their route involved an acetonide protection 
of the dimethyl ester of L-tartaric acid, followed by LAH reduction to produce diol 1.9.1, 
which was converted to bis iodo derivative 1.9.2 in two steps. Treatment of the iodo 
intermediate 1.9.2 with thiomethylmethylsulfoxide carbanion furnished 1.9.3 as a mixture 
of diastereomers. Cleavage of ketal and thioketal was accomplished by treatment with 
Amberlyst resin to produce the C2-symmetric diol 1.9.4. Treatment of the diol 1.9.4 with 






















Scheme 1.9. Synthesis of enantioenriched 4-HCPs from L-tartaric acid 
 
 
1.3.3. Non-enzymatic desymmetrization or kinetic resolution 
 Noyori et al. reported a direct enantioselective reduction of a prochiral 1,3-
diketone using a chiral hydride reducing agent, (S)-BINAL-H (L1), derived from C2-
symmetrical (S)-BINOL (Scheme 1.10).8 Enantioselective reduction of 1,3-
cyclopentenedione using L1, followed by acetylation provided 4-acetoxy-2-
cyclopentenone in 65% yield and 94% ee.  
 
 
Scheme 1.10. Noyori’s BINAL-H reduction of 1,3-diketones 
 
 Transition metal catalyzed approaches have also been used to synthesize optically 
enriched 4-HCPs. In 2005, Gais et al. (Scheme 1.11) reported an allylic displacement 




























































conditions using the Trost ligand (R,R)-L2.19 Alcohol 1.11.2 was obtained in 87% yield 
and 96% ee, and was converted to (S)-4-tert-butyldimethylsilyloxy-2-cyclopentenone, 
(S)-1.4.3, in 56% yield over three steps. Recently, Reiser’s group reported a palladium 
catalyzed kinetic resolution of racemic 4-O-acyl- (1.4.1) or O-boc (1.11.3) protected 4-
hydroxy cyclopentenone by using the Trost ligand (R,R-L2).20 They explored a number 
of heteroatom-based nucleophiles to obtain the 4-substituted-cyclopentenones (1.11.4) in 
excellent yields and enantiomeric ratios.  
 
 
Scheme 1.11. Pd-catalyzed synthesis of 4-HCPs using Trost ligand (R,R)-L2 
 
Several groups have investigated the desymmetrization of cyclopentanoid meso epoxides 
followed by β-elimination of a leaving group to achieve a short synthesis of 4-hydroxy-2-
cyclopentenones (Scheme 1.12). However, only a few methods in this category provide 
4-HCPs in high enantiopurity.  Leighton and Jacobsen reported the asymmetric ring 
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(L3), to afford the trans-disubstituted cyclopantanone 1.12.2.21 Treatment of azide 1.12.2 
with alumina furnished the desired (R)-4-trimethylsilyloxy-2-cyclopentenone 1.12.3 in 
77% overall yield and 94% ee (Scheme 1.12). Another catalytic approach to epoxide 
opening was described by Shibasaki et al., who carried out the (S)-GaLB catalyzed 
enantioselective opening of the cis-epoxide giving cyclopentanoid in 90% yield and 91% 
ee (Scheme 1.12).22 In this process, catalyst plays a dual role, one as a Lewis acid at the 
gallium centre promoting the ring opening by coordinating to epoxide, and secondly as a 
Bronsted base at the lithium binaphthoxide moiety by deprotonating the incoming thiol 
nucleophile. The product thioether 1.12.5 was subjected to oxidation to furnish α-sulfinyl 
ketone, which underwent pyrrolytic β-elimination yielding the desired enantioenriched 

















































1.4. Synthetic Applications of 4-HCPs 
 
1.4.1. Synthetic approaches to prostaglandins from 4-HCPs 
 4-HCPs have been heavily employed in the synthesis of prostaglandins. This 
section provides a highlight of the major approaches that have targeted the synthesis of 
the optically enriched PGs using 4-HCPs as the chiral building block.  
 Noyori’s group accomplished a three-component coupling to install both α and β 
chains in a one-pot sequence (Scheme 1.13).8 The conjugate addition of the vinylcuprate 
1.13.1 to the enone (R)-1.4.3, resulted in the lithium enolate that was trapped as a tin 
enolate 1.13.2 and was subjected to react with the allyl iodide 1.13.3 to provide methyl 
ester of PGE2 1.13.4 in 78% yield. The stereocenter in the β side chain had been 
preinstalled by using Noyori’s BINAL-H reduction.  
 
 
Scheme 1.13. Noyori’s three component synthesis of PGs 
 
Danishefsky’s group reported an elegant approach using a conjugate addition of the silyl 




























conjugated addition of cuprates, in the present case mercuric chloride mediated addition 
happened syn to the C-4 stereochemistry of the enone 1.4.3 and an in situ migration of 
silyl group led to a silyl enol ether 1.4.3 that was subjected to Lewis acid mediated aldol 
with an α,β unsaturated aldehyde 1.14.4. The trans geometry of the olefin and the 
stereochemistry of the hydroxyl group in the side chain were established by palladium-
mediated allylic transposition of the acetate at a later stage in the synthesis. This was the 
only PG synthesis that involved substrate control to set all the stereocenters (including 




Scheme 1.14. Danishefsky’s synthesis of PGs 
 
 Despite the attractiveness of the Noyori’s three component coupling approach for 
the PG synthesis,8 there were several synthetic limitations associated with it. The most 
noticeable were the problems of enolate equilibration and β-elimination of the silyloxide. 
Johnson and coworkers reported a synthesis of α-iodoenones that proved really useful in 
overcoming the problems faced in conjugate addition-alkylation approaches.13 Suzuki 























Followed by conjugate addition of the vinyl cuprate 1.15.4 provided the desired product 
1.15.5 (Scheme 1.14).23 
 
 
Scheme 1.15. Suzuki’s route to PGs  
 
1.4.2. Application of 4-HCPs in non-PG natural product syntheses 
 The developments in the prostaglandin chemistry proved the synthetic potential of 
this building block in undergoing multicomponent coupling reactions. In addition, 
stereodirecting ability of the stereogenic center present on this carbocycle, combined with 
the high functional group density displayed over the five-carbon cyclic skeleton attracted 
the attention of various research groups to utilize 4-HCP as a building block in the 
synthesis of complex natural products.  
 Corey’s group reported enantioselective synthesis of pentacycloanammoxic acid, 
a highly strained and naturally occurring fatty acid from the anaerobic microbes 
Candidatus brocadia anammoxidans.24 The enone (R)-1.4.3 was converted to 4-silyl-
substituted cyclopentenone (R)-1.16.1 in three steps involving conjugate addition, 
























stereoselective [2+2] photochemical cycloaddition of  (R)-1.16.1 with the cyclobutene 
1.16.2 to obtain cyclopentanone adduct 1.16.3 in high enantiopurity, which was further 
transformed to desilylated cyclopentanone 1.16.4 in four steps. 1.16.4 was subjected to α-
diazoketone formation followed by photoinduced Wolff ring contraction and ester 
hydrolysis to produce carboxylic acid 1.16.5. Further homologation using the Wittig 




Scheme 1.16. Corey’s synthesis of (+)-pentacycloanammoxic acid 
 
Trauner’s group reported the synthesis of the tricyclic framework found in the  
guanacastepene family of natural products.25 One of the key precursors, a trisubstituted 
enone 1.17.2, was generated from 4(R)-O-acetyl-2-cyclopentenone in six steps. The 
synthesis involved a conjugate addition of a cuprate followed by acid-promoted 
elimination of the acetate. A second conjugate addition of methylcuprate in the presence 
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1.17.1, which was further transformed to 1.17.2 in two steps. The trisubstituted enone 
1.17.2 was reacted with iodo compound through a challenging cuprate conjugate addition 
in the presence of a Lewis acid (Scheme 1.17). 
 
  
Scheme 1.17. Trauner’s synthesis of guanacastepene framework 
 
 Overman’s group reported the synthesis of a spongian diterpene marine natural 
product (Scheme 1.18).26 They employed 4(R)-O-acetyl-hydroxy cyclopentenone (R)-
1.4.1 to obtain a tricarbonyl intermediate 1.18.5 in six steps. The synthesis started with 
combining 4(R)-1.4.1 with silyl ketene acetal 1.18.1 to afford a cyclopentenone that was 
subjected to acidic cleavage of diacetal group. Methylation with dimethylsulfate to obtain 
the α-hydroxy ester 1.18.2 in 55% yield. The addition of the tert-butylcuprate reagent to 
1.18.2 in the presence of TBSCl led to trans-substituted cyclopentenyl silyl ether, which 
was subjected to Takai methylation to produce methyl enol ether 1.18.3.  Treatment of 
1.18.3 with oxalic acid led to selective cleavage of methyl enol ether to provide ketone 












































with Pb(OAc)4 in methanol, formed tricarbonyl intermediate 1.18.5, which was further 
transformed to spongian diterpene 1.18.6. 
 
 
Scheme 1.18. Overman’s synthesis of spongian diterpenes 
 
Recently Reiser’s group reported an enantioselective synthesis of the guaianolide 
arglabin via a copper(I)-catalyzed asymmetric cyclopropanation (Scheme 1.19).27 Methyl 
cuprate addition to OPMB protected enone 1.19.1 provided trans substituted silyl enol 
ether 1.19.2 that was subjected to Ni(II)-catalyzed cross coupling with 
trimethylsilylmethylenemagnesium chloride to obtain 1.19.3. Lewis acid mediated 
Sakurai addition of the silane 1.19.3 to the aldehyde carbonyl group of 1.19.4  followed 
by exposure to basic conditions resulted in  hydrolysis of oxalic ester, cyclopropane ring 
opening and lactonization in the same pot to give bicyclic lactone 1.19.5 as a single 











































Scheme 1.19. Total synthesis of arglabin 
 
1.5. Results and discussion 
 As discussed in the previous section, several methods are known for the 
preparation of optically enriched O-protected-4-hydroxycyclopentenone. One of the most 
efficient routes, in terms of overall yield and enantiopurity is via enzymatic 
desymmetrizataion developed by Deardorffs’s group that provides enone (S)-1.4.3 in 
seven-steps (see Schemes 1.5 to Schemes 1.7).12,15,28 To obtain the enone (R)-1.4.3 it 
requires either seven-step synthesis15 that include a germ lipase catalyzed acetate 
hydrolysis that consumes ten days (Scheme 1.7); or a nine-step route16 that requires 
switching of the acetate function with pivolyl group (see Scheme 1.8). The acetate to silyl 
ether conversion is significant considering its applications in the synthesis. This is 
because a silyl group can be removed selectively under milder conditions than an acetate 
or other ester groups, and without the risk of undesired side reactions that may occur 
































 Also, it is worth noting that majority of the available methods to procure 4-O-
protected hydroxy-cyclopentenones install the acetate group first that is later transformed 
to O-silyl group by additional synthetic steps. Only method which leads to a silyl 
protected hydroxy cyclopentenone without the intermediacy of an acetate function is the 
Jacobson’s enantioselective chromium-salen-catalyzed opening of the meso-epoxide with 
TMS-azide (see Scheme 1.12).21 Though Jacobson’s method provides the TMS-protected 
enone in high yield and optical purity, it suffers from two major drawbacks: first, it 
requires the elimination of an equivalent amount of hydrazoic acid to form the desired 
enone, hence not suitable for large scale synthesis of 4-HCPs because of the hazardous 
by-product formation, and second, TMS protected HCPs have not found much interest 
from synthetic chemists because of the high acid and base sensitivity of the OTMS group.  
 Aube group has utilized 4-HCP in the past in context with the total synthesis 
projects21 and synthesized the required HCPs by the Deardorff protocol. Considering the 
diverse synthetic applications of HCPs, we aimed to develop an alternative approach 
toward the synthesis of enantioenriched 4-HCPs with the following features: 
1. A concise route involving a non-enzymatic catalytic means of introducing 
asymmetry, that would help to minimize the solvent waste generated in the process. 
The enzymatic routes in current practice generate copious amounts of the solvent 
waste  beacause of the extensive solvet extraction required to procure the product. 
2. A stereodivergent route that should provide equal access to either of the 
enantiomers of 4-HCP. 
3. A flexible route toward the synthesis 4-HCP with different protecting groups 
without adding additional synthetic steps. 
 21 
 In considering the enzymatic route (Figure 1.4a), we noted that it involves two 
stereocontrolled steps: (1) the synthesis of meso-diacetate 1.4B (i.e., only cis and not 
trans) that is generally accomplished from cyclopentadiene by 1O2 chemistry or by 
epoxidation, followed by acetolysis of a derived π-allyl species29 and (2) the enzyme-
controlled enantioselective hydrolysis to obtain mono acetate 1.4C.12 In contrast, the 
corresponding trans-diol 1.4F (Figure 1.4b) would no longer have planar symmetry but 
instead be a chiral, C2-symmetric molecule. Thus, it would no longer be necessary to 
differentiate the two identical alcohol groups in future steps. Moreover, we felt that it 
would be possible to readily prepare diol 1.4F using the known asymmetric conversion of 
diketone 1.4D to diol 1.4E,11 followed by ring-closing metathesis. Thus, only a single 
stereoselective reaction would be required in the entire synthesis. 
 
 
Figure 1.4. Stereochemical analysis of the enzymatic route 
 
To realize this goal, earlier efforts by Angelica Meyer, a former graduate student in 
Aube group led to the development of a route towards the synthesis of TIPS-protected 






























enone (R)-1.20.3 via mono-TIPS protection of the C2-symmetric diol (R,R)-1.20.1 
followed by ring-closing metathesis. She synthesized and employed the corresponding 
iodo derivative (R)-1.20.4 in her efforts towards the asymmetric synthesis of 
cylindricine C.    
 
 
Scheme 1.20. Synthesis of (R)-4-hydroxy-2-cyclopentenone by 
Angelica Meyer 
 
 Our goal in the present work was to develop this route for the HCP synthesis with 
different protecting groups of wide range of chemical nature and to determine the 
enantiomeric ratio of the resulting enone product by using a suitable analytical technique.  
In the current work, we also showed the utility of this route to access either of the 
enantiomers of the enone. Further, a few synthetic applications of the trans diol (Figure 
1.4) have been shown highlighting the utility of these intermediates in undergoing 
stereospecific transformations. 
 
1.5.1. Synthesis of (3R, 5R)-hepta-1,6-diene-3,5-diol 
Commercially available acetyl acetone was converted to 1,5-dichlorodione using the 
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mixture of AlCl3 and chloroacetyl chloride in nitrobenzene followed by distillation 
provided 1,5-dichlorodione 1.21.2 as a clear liquid. Dichlorodione 1.21.2 is an unstable 
compound that turns into a dark solid on standing at room temperature. It was converted 
to copper bis(dichloroacetylacetonate) 1.21.3 by treating with copper (II) acetate resulting 
in a light green solid that can be safely stored at room temperature for several weeks. We 
prepared up to 56 g of the copper salt 1.21.3 by following the method reported in the 
journal of Organic Syntheses.31 The copper salt was converted to the corresponding 
dichlorodione just before performing the following hydrogenation step on treatment with 
aq sulfuric acid (10%). Hydrogenation of dichlorodione 1.21.2 was performed in the 
presence of 0.25 mol% (S)-BINAP-Ru(II)Cl2 in methanol at 1200 psi at 80ºC. (R,R)-
Dichlorodiol 1.21.4 was obtained in 38-40% yield by crystallization from 2:1 mixture of 
hexane/dichloromethane. Although we could reproduce the 40% yield of this reaction as 
reported by Rychnovski,31 others have reported yield up to 68% by using modified 
version of the ruthenium catalyst.33 
 
 
Scheme 1.21. Preparation of (2R, 4R)-1,5-dichloro-2,4-pentanediol 
 
 We used Hanson’s method to convert dichlorodiol 1.21.5 to diene diol 1.20.1 

























generated by treating trimethylsulfonium iodide with n-butyl lithium at -30 ºC provided 
(3R,5R)-diene diol 1.20.1 (Scheme 1.22). It was important in this reaction to use freshly 
prepared trimethylsulfonium salt obtained by mixing an equimolar ratio of dimethyl 
sulfide and methyl iodide. The salt was recrystallized from ethanol and was dried for 24 
hours under high vacuum before use.  
 
 
Scheme 1.22. Synthesis of (3R,5R)-hepta-1,6-diene-3,5-diol 
 
Having prepared the required diene diol, our next objective was to derivatize it 
with suitable protecting groups. We chose TBS, 4-methoxy-benzyl, and acetate 
functional groups for further derivatization. We chose protecting groups according to 
their diverse chemical sensitivity and applications found in the literature.  
 
1.5.2. Synthesis of mono-protected diols 
 Mono TIPS protection of 1.20.1 was performed as previously reported by 
Angelica Meyer (Scheme 1.23).30 Treatment of the diene diol with n-BuLi followed by 
the addition of TIPSCl at -78 ºC generated OTIPS protected diol 1.20.2 in 96% yield. 
TBS protection was tried under similar conditions (by employing TBSCl in place of 
TIPSCl) however only starting material was observed, presumably because of the 
extremely hydroscopic nature of the solid TBSCl reagent   Ultimately, the OTBS product 










Scheme 1.23. Monosilylation of (3R,5R)-diol 1.21.1 
 
 Acetate protection of the (3R,5R)-diol 1.20.1 using triethylamine acetyl chloride 
provided mono acetate compound only in 10% yield. The addition of DMAP led to a 
mixture of mono and diprotected products. Finally, the monoprotected acetate was 
obtained in 84% yield by treating diol with trimethyl orthoactetate followed by stirring in 




Scheme 1.24. Mono acylation of 
(3R,5R)-diol 1.20.1 
 
 4-Methoxybenzyl protection was tried using freshly prepared 4-methoxybenzyl 
trichloroimidate. However, it led to a mixture of mono- and diprotected products. Finally 



















Scheme 1.25. 4-Methoxybenzyl protection of  
(3R,5R)-diol 1.21 
 
1.5.3. Synthesis of cyclopentene diol and enones 
 Ring-closing metathesis of diene diol 1.20.2 was performed with both Grubbs I35 
or Grubbs II36  (2–3 mol%) in DCM and provided 49–53% yield in 24 h at room 
temperature. Increasing the catalyst loading or dilutions did not improve the reaction 
yields. The optimum yield was obtained by performing the reaction at 50 ºC using 3 
mol% of Grubbs I catalyst. Other mono-protected dienes were subjected to RCM using 
Grubbs I to obtain the cyclized products in 88-92% yield (Scheme 1.26).  
 
 
Scheme 1.26. Synthesis of cyclopentenols via  
ring-closing methathesis (RCM) 
  
Finally, oxidation of the cyclopentenols with pyridinium chlorochromate provided the 
targeted O-protected-4-hydroxy-2-cyclopentenones in excellent yields (Scheme 1.27). 
The enantiomeric ratios of the products 1.20.3, 1.4.3 and 1.4.1 were determined by chiral 
gas chromatography (GC) by using Astec Chiraldex B-DM fused silica column. The 
OPMB protected enone 1.27.1 could not be analytically resolved after several attempts 
OH OH 4-methoxybenzyl chlorideNaH, DMF OH OPMB
66%
(3R,5R)-1.25.1(3R,5R)-1.20.1






















using chiral gas chromatography. Finally, the enantiomeric ratio of the OPMB enone 
1.27.1 was determined by high pressure liquid chromatography (HPLC) method by 
developing suitable conditions on CHIRALPAK IC column. 
 
 
Scheme 1.27. Synthesis of 4(R)-O- 
protected-hydroxycyclopentenones 
 
 This route can be adopted for the synthesis of (S)-1.27.1 by simply using (R)-
BINAP in the hydrogenation step (Scheme 1.28). Besides no longer requiring different 
schemes for preparing the two enantiomers, the present route proceeds in acceptable 
overall yields from commercially available starting materials (26–32%) and compares 
favourably in number of steps compared to other methods (5 steps from 1.21.2 to either 
(R)- or (S)-1.27.1 as opposed to 9 steps by enzymatic routes discussed above).  
 
 
Scheme 1.28. Synthesis of (S)-4-O-TIPS-cyclopentenone 
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Another useful 4-HCP is the α-iodo derivative of enone 1.29.1, which has found 
applications in the synthesis of prostaglandins (see Scheme 1.14).23 Thus, we transformed 
both (R)- and (S)-1.20.3 into iodides (R)- and (S)-1.29.1 following a previously reported 
procedure13 as shown in Scheme 1.27. 
 
 
      Scheme 1.29. Iodination of enone 1.20.4 
1.5.4. Derivatives of HCP 
 Just as 4-HCPs have been broadly employed in synthesis, the reduced alcohol 
precursor introduced herein should be of comparable utility. We have synthesized a few 
derivatives of the allylic alcohol 1.26.1. Thus, epoxidation of allylic alcohol 1.26.1 
provided 1.30.2 exclusively in 66% yield (likely due to a reinforcing combination of 
Henbest-like delivery of peracid and avoidance of the large OTIPS group37). Epoxide 
opening occurred regioselectively with sodium azide to provide the highly substituted 
cyclopentane 1.30.2 in 69% yield. The stereo- and regiochemistry of the product 1.30.3 













Scheme 1.30. Stereo and regioselective synthesis of azido derivatives  
of cyclopentane 
  
In addition, amino-substituted cyclopentene derivatives were made using simple 
displacement chemistry (Scheme 1.31). Mitsunobu displacement of the allylic alcohol 
1.26.1 with phthalimide gave 1.31.1 in 68% yield. Further subjecting to silyl deprotection 
with TBAF followed by PCC oxidation provided the 4-amino substituted enone 1.31.3 
via the alcohol intermediate 1.31.2. Displacement of allylic alcohol 1.26.1 with adenine 






























Scheme 1.31. Cycopentene derivatives via Mitsunobu displacement 
 In summary, we have demonstrated a convenient synthesis of 4-HCPs, an 
important class of privileged building blocks for organic synthesis. The route is scalable 
to  >4 g scale of the diol intermediate 1.26.1 and provides access to either enantiomeric 
series of 4-HCPs using the identical route. Also this method falls in the category of few 
known methods capable of providing silylated enones in excellent optical purities without 
the intermediacy of an acetate group. This approach can be used to obtain the 4-HCPs 
with different protecting  groups in six steps from the commercially  available 
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Development of a Stereodivergent Approach Toward the Synthesis of 3,5-Dihydroxy 
Six-Membered Carbo- and Heterocyclic Rings 
  
2.1. Introduction  
 1,3-Cyclohexanediol and 3,5-dihydroxy piperidine structural motifs are present in 
numerous complex natural products (Figure 2.1). Many of these natural products are 
biologically active. For example, 1α,25-dihydroxy D3 (2.1G), a major metabolite of 
vitamin D3, have wide range of biological activities including mineral homeostasis, 
cellular differentiation and proliferation, angiogenesis,  and apoptosis.38,39 7-Deoxy-6-
epi-castanospermine (2.1H), a trihydroxy indozolidine is an inhibitor of 
amyloglucosidase.40 Alkaloid 2.1E is a competitive inhibitor of α-D-glucosidase, which 
blocks the processing of N-linked glycoproteins.  Polyhydroxy nortropane alkaloids 
calystegine B3 (2.1I) and A7 (2.1J) and related alkaloids of this class show potent 
inhibitory activity against β-glucosidase and galactosidase.41  
 The interesting biological properties of these natural products have inspired many 
to utilize polyhydroxylated diols or piperidine structural motifs for the development of 
new molecules of pharmaceutical or biomedical applications. Polyhydroxylated 
piperidines, also called iminosugars, have recently received much interest as glycosidase 
inhibitors with applications in the treatment of cancer and AIDS.42 More specifically, 3,5-
dihydroxy piperidines, which are deoxy analogs of imino sugars, are substructures in 
compounds active in the treatment of Alzheimer’s disease43 and schizophrenia.44,45 Figure 
2.2 shows examples of the compounds containing 1,3-cyclic diol moieties, which have 
 32 
been reported for diverse range of biological activities. For example, salacinol-containing 
alditols glycosidase inhibitors (2.2E) as antidiabetic agents,46 and fused tricyclic 
 
 
Figure 2.1. Examples of natural product structures containing a 1,3-cyclohexanediol  
or 3,5-dihydroxy piperidine motif 
 
 
carbamates (2.2F)  containing thienopyrimidinedione (2.2A) as ACC (acetyl-coA 
carboxylase) inhibitors47, furopyrimidines (2.2B) as antihypertensive agents48 and aryl 
alcohol compounds (2.2C) as plasminogen activator therapeutic agents for HIV patients49 
have been reported. Piperidine or tetrahydropyran based phosphatidyl inositol mimics 














































































potent anti-inflammatory agents.50 The presence of six-membered cyclic 1,3-diol motif in 
several natural and synthetic compounds of biological interest makes these attractive 
targets for synthesis. The following section provides a survey of the existing synthetic 
approaches for the synthesis of cyclohexane diols and dihydroxypiperidines. 
 
 
Figure 2.2. Synthetic compounds of therapeutic importance containing six-membered 
carbo- or heterocyclic-1,3-diol motif 
 
2.2. Synthesis and applications of cyclohexane-1,3-diols 
 1,3-Cyclohexanediols are attractive targets for synthesis because of their presence 
in important natural product structures and biologically important molecules. Different 
approaches for diastereo- and enantioselective synthesis of 1,3-cyclohexanediols and 
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low selectivity.51–54 A few examples of desymmetrization of cis-1,3-cyclohexanediol 
using enzymatic resolution have previously been reported.55–59   
 In 1990, Suemune group reported a nine-step synthesis of trans-(R,R)-
cyclohexene diol 2.1.7 via enzymatic desymmetrization (Scheme 2.1).58 They performed 
the benzylation of commercially available cis-phloroglucitol 2.1.1 ($73 for 1 g from 
Sigma) with sodium hydride and benzyl chloride to obtain 2.1.2 as a monobenzylated 
product in 40% yield. Subsequent diacetylation of 2.1.2 provided the meso diacetate 
product 2.1.3 in 91% yield. Porcine liver esterase (PLE)-catalyzed hydrolysis of diacetate 
2.1.3 produced desymmetrized monoacetate 2.1.4 in 62% yield and 87% ee. The 
inversion of the alcohol stereocenter in 2.1.4 via mesylation and elimination, followed by 
hydrogenation produced 2.1.5 in 77% yield over three steps. Triflate formation followed 
by silica gel mediated elimination resulted in diacetate 2.1.6 in 70% yield. Finally, 
Pseudomonas fluorescens lipase (PFL)-catalyzed hydrolysis of the diacetate 2.1.6 
produced mono acetate 2.1.7 in 77% yield.  
 
 






















AcO OAc 77%70% HO OAc77%
2.1.1 2.1.2 2.1.3 2.1.4
2.1.5 2.1.6 2.1.7
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Later, in 1992, Suemune group reported the synthesis of both cis-(1S,5S)-2.2.3 
and trans-1R,5S)-2.2.3 cyclohexane-1,3-diols  by utilizing enantioenriched triol 
(1S,3R,5S)-2.1.4 (Scheme 2.2).59 The trihydroxy compound 2.1.4 was subjected to Swern 
oxidation. Oxidation of the hydroxyl function as well as acetate elimination under the 
Swern oxidation conditions produced the enone 2.2.1 in 92% yield. Reduction of the 
ketone function in 2.2.1 with sodium borohydride produced the syn dihydroxy compound 
2.2.2 in 90% yield. Treatment of 2.2.2 with benzoyl chloride in pyridine provided the 
(1S,5S)-diol derivative 2.2.3 in 83% yield. Mitsunobu inversion of the alcohol 
stereocenter in (1S,5S)-2.2.2 with acetic acid as nucleophile formed the acetylated 
product (1R,5S)-2.2.4 that was hydrolyzed to produce mono-benzylated trans-diol 




Scheme 2.2. Suemune’s synthesis of enantioenriched cis and  
trans-cyclohexene-1,3-diols 
 
They further applied these newly developed cyclohexanediol building blocks for the 
synthesis of lactone moiety of compactin (Scheme 2.3a) and toward a formal synthesis of 
































of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase, the rate-limiting enzyme in 
cholesterol biosynthesis. The Suemune group prepared the compactin lactone in five 
steps from 2.3.1 that was obtained by the above-described route. Ozonolysis of the 
cyclohexene diol 2.3.1, Jones oxidation and esterification with diazomethane produced 
diester 2.3.2 in 44% yield over three steps. Diester 2.3.2 was hydrolyzed using potassium 
carbonate in methanol and was subjected to acid-catalyzed lactonization to afford the 
desired lactone product 2.3.4. For the synthesis of quinic acid they utilized a trans diol 
(1R,5S)-2.3.1.59 The synthesis started with the diastereoselective epoxidation of the diol 
2.3.1 with m-CPBA to produce epoxide 2.3.5 as a single diastereomer. Epoxide opening 
of 2.3.5 with acetic acid followed by acetylation produced the triacetate 2.3.6. Palladium-
catalyzed hydrogenation followed by ruthenium-mediated oxidation afforded the 








Scheme 2.3. Applications of cyclohexanediols toward, a) the synthesis of  
compactin lactone b) formal synthesis of quinic acid  
 
 In 2007, Sweeney’s group reported a chiral pool approach toward the synthesis of 
enantioenriched 1,3-cyclohexanediols. They prepared both (R,R)- and (S,S)-
cyclohexanediols via regio- and diastereospecific hydroxyselenation of cyclohex-2-enyl 
phenylglycinates.60 Racemic allylic bromide 2.4.1 was treated with DBU and (R)-
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this approach was the regioselective hydroxyselenylation of 2.4.2 with N-
phenylselenylphthalimide and camphorsulfonic acid (CSA) to produce inseparable 
diastereomeric mixture of 2.4.3 and 2.4.4. They proposed that a hydrogen bonding 
interaction of the selenylphthalimide electrophile with the glycinate moiety directed the 
incoming electrophile to the syn face of the olefin 2.3A (Fig 2.3) resulting in selenium 
ion 2.3B, which is opened by the hydroxyl nucleophile regioselectively by an axial 
attack. Subjecting 2.4.3 and 2.4.4 mixture to deselenylating conditions produced the trans 
diols 2.4.5 and 2.4.7, which were separated by column chromatography. The isolated 
diastereomers 2.4.5 and 2.4.7 were converted to monosilylated products (S,S)-2.4.6 and 


























































Figure 2.3. Mechanistic rationale for diastereo- and regioselective 
hydroxyselenylation 
 
 In 2001, Kalkote group reported an enzymatic synthesis of both enantiomers of 
diprotected trans-3,5-dihydroxy-1-cyclohexanone starting from phloroglucitol 2.1.1.61 
Triacetylation of 2.1.1 followed by enzyme-mediated hydrolysis afforded the diacetate 
compound 2.5.1. Silylation of 2.5.1 using TBSCl followed by PLE catalyzed 
desymmetrization provided the enantioenriched monoacetate product 2.5.2. THP 
protection of the 2.5.2 and subsequent basic hydrolysis formed the alcohol 2.5.3. The 
alcohol stereocenter in 2.5.3 was inverted via a Mitsunobu displacement with benzoic 
acid followed by hydrolysis to obtain 2.5.4. Compound 2.5.4 bearing two orthogonal 
protecting groups was used as a common precursor to access both the enantiomers of the 
diol trans-3,5-dihydroxy-1-cyclohexanone. THP protection followed by TBS 
deprotection produced the pseudo C2-symmetric cyclohexanol 2.5.5. Oxidation of the 
alcohol function provided THP protected trans-3R,5R-dihydroxy-1-cyclohexanone R,R-
2.5.6. Alternatively, silyl protection of the hydroxyl group followed by THP deprotection 
under mildly Lewis acidic conditions formed bis-silylated triol 2.5.7. Subsequent 




























Scheme 2.5. Kalkote’s approach toward the synthesis of enantioenriched  
3,5-dihydroxy cyclohexanone 
  
In 2006, Bäckvall’s group reported an elegant chemoenzymatic approach for the 
synthesis of enantioenriched 1,3-cyclohexanediols by enzymatic desymmetrization of an 
equilibrating mixture of cis and trans cyclohexane-1,3-diols (Scheme 2.6).62 A cis/trans 
mixture of 1,3-cyclohexanediol 2.6.1 was converted to meso diacetate 2.6.2 by combining 
ruthenium-catalyzed epimerization with Pseudomonas cepacia lipase (PS-C)-mediated 
acylation. Hydrolysis of the meso diacetate 2.6.2 with Candida antarctica Lipase B 
(CALB) produced the enantioenriched cis monoacetate (S,R)-2.6.3 in 97% yield and 
>99% ee. Hydrolysis of the cis diacetate 2.6.2 with lithium hydroxide followed by 
CALB-catalyzed monoacylation produced the enantiomeric (R,S)-2.6.4. Combining Ru-
catalyzed epimerization with CALB-catalyzed transesterification, 2.6.4 was converted to 
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Scheme 2.6. Bäckvall’s chemoenzymatic approach toward the synthesis of 
enantioenriched 1,3-cyclohexanediols 
 
2.2. Synthesis and applications of 3,5-dihydroxy piperidines  
 In 2006, Cossy’s group reported the synthesis of enantioenriched 3,5-dihydroxy 
piperidine via a ring-expansion approach from 4-hydroxyproline.63 They developed a 
seven-step route to obtain N-benzyl-3,5-dihydroxy piperidine from 4-hydroxyproline. 
Hydroxyproline 2.7.1 was converted to silyl-protected hydroxyl proline 2.7.2 in three 
steps. Subsequent reduction of the carboxylic acid group with LAH produced alcohol 
2.7.3 in excellent yield. Activation of the alcohol as triflate followed by treatment with 
triethylamine produced a [5,3]-bicyclic intermediate 2.7.4 that underwent ring expansion 
















































Scheme 2.7. Cossy’s ring-expansion approach towards  
enantioenriched 3,5-dihydroxy piperidines  
 
 In 2006, Bäckvall group reported synthesis of both racemic and asymmetric 
synthesis of 3,5-disubstituted piperidines.64 They synthesized a cis/trans mixture of 3,5-
dihydroxy piperidine from the commercially available N-benzylglycinate (Scheme 2.8). 
The glycinate 2.8.1 was N-alkylated with chloroacetone to obtain 2.8.2. Intramolecular 
Claisen condensation of 2.8.2 followed by trapping of the enolate with acetic anhydride 
resulted in β-acetoxyenone 2.8.3. The deacetylation of 2.8.3 with CALB resulted in 
diketone 2.8.4 that was subjected to ruthenium-catalyzed transfer hydrogenation 
conditions to obtain cis/trans mixture of 2.8.5 in 70% yield.  
 
 








































































Bäckvall’s approach for the synthesis of enantioenriched 3,5-
dihydroxypiperidines involved chemoenzymatic dynamic kinetic asymmetric 
transformation of a racemic cis/trans mixture of 3,5-dihydroxy-piperidines (Scheme 2.9). 
PS-C-catalyzed monoacylation of cis/trans mixture of 2.8.5 resulted in 2:3 mixture of 
(3R,5R)-2.9.1 and (3R,5S)-2.9.2. The trans product (3R,5R)-2.9.1 and the cis product 
(3R,5S)-2.9.2 were isolated in 29% yield and 45% yield respectively with ee > 98% by 
chromatographic separation. Alternatively, PS-C mediated acylation at 50 ºC resulted 
exclusively in meso-diacylated compound 2.9.3 that was hydrolyzed with sodium 
hydroxide in methanol to produce meso-diol (R,S)-2.8.5. A second PS-C-catalyzed 




Scheme 2.9. Bäckvall’s chemoenzymatic approach toward the synthesis of 
enantioenriched 3,5-dihydroxy piperidines 
 
2.3. Results and discussion 
 As discussed in the previous section, 3,5-dihydroxy six-membered carbo- and 
heterocyclic rings are of considerable interest for both the synthetic and pharmaceutical 
community because of their presence in natural product structures as well as emerging 






































routes for the synthesis of enantioenriched 1,3-cyclohexanediol and 3,5-
dihydroxypiperdines involve multiple steps, extensive use of protecting group chemistry, 
multiple enzymes, and transition metal catalysts. We believe that a shorter route that can 
provide these important building blocks in significant quantities and high enantiopurities 
would be of general use to fulfill existing needs and may encourage researchers to further 
explore the synthetic and pharmaceutical applications of these versatile building blocks. 
 Having developed a concise route for the synthesis of enantioenriched 
cyclopentenones (Chapter 1), we aimed to utilize the Rychnovski’s dichlorodiol31 for the 
synthesis of six-membered rings (Figure 2.4). The proposed approach was most plausibly 
extendable for the synthesis of six-membered heterocyclic 1,3-diols. In this work, we 
describe the development of a unified strategy for the stereodivergent synthesis of 




Figure 2.4. A novel approach toward  
six-membered cyclic-1,3-diols 
  
To begin with the synthesis of carbocyclic diols, we initially considered using dithiane 
based carbanion nucleophile. 1,3-Dithianes were introduced in 1965 by Corey and 
Seebach as reagents for C–C bond formation by nucleophilic displacement and carbonyl 
addition.65 Schreiber group reported the application of this chemistry in the total 






(Nuc = C, N, O or S- based nucelophiles)




Scheme 2.10. Schreiber’s synthesis of talaromycin B 
In 1994, Tietze group reported the application of silyl-dithiane based carbanion for the 
synthesis of homocoupled diol 2.11.3.67 They performed the opening of epoxide 2.11.2 
with TMS dithiane 2.11.1 followed by crown ether promoted 1,4-Brook rearrangement to 
reveal the second carbanion that reacted with another equivalent of epoxide 2.11.2 to 
furnish a homocoupled diol 2.11.3 (Scheme 2.11). Further advancement of this chemistry 
for multi-component reactions to access complex polyols has been well studied by Smith 
and coworkers.68,69 However, to our surprise, there are very few examples in literature of 
the use of silylated dithianes for intramolecular C–C bond formation. In 1994, 
Schaumann reported the reaction of TMS-dithiane (2.11.1) with a dual electrophilic 
substrate 2.11.4 bearing an epoxide and tosylate functional groups.70 Nucleophilic 
addition of the dithiane carbanion, silyl migration followed by intramolecular 
























Scheme 2.11. Earlier examples of TMS-dithiane  
               as carbanion nucleophile 
 
 A recent example involving dithiane mediated cyclization of a bis epoxide to 
obtain carbanucleosides was reported by Linclau’s group (Scheme 2.11).71,72,71 They 
proposed that opening of the epoxide 2.12.2 with the lithiated 2-silyl-1,3-dithiane 
followed by 1,4-Brook rearrangement generated the carbanion 2.12.4. Newly generated 
carbanion 2.12.4 attacked the second epoxide regioselectively at the internal carbon 
leading to the formation of a five-membered ring 2.12.5. To direct this route for the 
synthesis of six-membered ring, it would require intramolecular attack of the in situ 
generated nucleophile to happen at the terminal carbon and not the internal carbon.  
 
 






























1. t-BuLi, -78ºC 

















We designed a modified substrate 2.13.2 similar to the one used by Schaumann 
(see scheme 2.11), bearing two differentially electrophilic carbons, an epoxide and a 
primary halide, which would undergo sequential C–C bond formation conceivably 
leading to a six-membered carbocycle (Scheme 2.12). The success of this approach 
would require control of the order and timing of three important chemical events taking 
place in this reaction. First, lithiated-1,3-dithiane 2.13.1 mediated chemoselective 
opening of the epoxide 2.13.2 in the presence of a primary halide to form an alkoxide 
2.13.3, which could in principle displace the halogen leading to an undesired furan 
product 2.13.5. However, a timely Brook rearrangement prompted by a polar solvent 
would mask the alkoxide by C- to O-transfer of the silyl group resulting in a reactive 
carbanion intermediate 2.13.4, hence ruling out the possibility of furan ring formation. 
Finally, intramolecular displacement of the chloride would provide the desired cyclized 
six-membered product 2.13.6. 
 
 
Scheme 2.13. Our design rationale for the synthesis of  
cyclohexane-1,3-diols 
   
S S
SiR3























Considering the robustness of the silyl protecting groups in synthesis and our own 
experience with the TIPS as a protecting group, we planned to explore the dithiane 
chemistry using a TIPS-protected substrate. Considering the possibility of the epoxide 
formation under strong basic conditions, we attempted the mono silylation under low 
temperature conditions (Scheme 2.14). Addition of 1 eq of n-BuLi to the precooled 
solution of dichlorodiol 1.20.4 in THF at -78 ºC was followed by the addition of 1 equiv 
of TIPSCl at the same temperature. Allowing the solution to warm to rt for 16h yielded 
the mono silylated product 2.14.1 in 68% yield. Next we monitored the progress of 
reaction while maintaining low temperature conditions. It was observed that the desired 
mono-silylated product formation occurred at -78 ºC; however, the progress of the 
reaction was very slow. Slowly allowing the reaction to warm to -40 ºC and maintaining 
the temperature at -40 ºC for 6 h led to complete consumption of the starting material. 
The reaction was quenched with saturated ammonium chloride at -40 ºC. The 
monosilylated product 2.14.1 was isolated in 92% yield, which was converted to epoxide 
2.14.2 in quantitative yield using powdered potassium hydroxide in anhydrous diethyl 
ether as solvent.   
 
 
Scheme 2.14. Synthesis of the epoxide substrate 
 
 Having prepared the required epoxide substrate 2.14.2, we reacted it with 
dithiane-based nucleophile (Scheme 2.15). Our objective was to promote the selective 
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literature that terminal epoxides can be opened at low temperature with dithiane-based 
carbanion nucleophiles; however the SN2 displacement of chloride is slow at sub-zero 
temperature.73 On the basis of this, we thought it would be possible to control the order of 
epoxide opening and halogen displacement by temperature control. The lithiation of TBS 
dithiane was carried out at room temperature with n-BuLi in a 9:1 mixture of 
THF/HMPA using n-BuLi as base. The resulting yellow solution was added to a pre-
cooled solution of the epoxide 2.14.2 in THF/HMPA (9:1) at -78 ºC. The reaction 
mixture was maintained at -78 ºC for 0.5 h and then raised to -40 ºC for 2 h. 
Consumption of the starting material was observed by TLC at -40 ºC, indicating opening 
of the epoxide. Further allowing the reaction to stir at rt for 18 h formed the cyclized 
product 2.15.3 in 88% yield. The disilyl cyclohexanediol 2.15.3 was treated with 1 M 
TBAF in THF to produce C2-symmetric 1,3-cyclohexanediol 2.15.4 in 94% yield. 
 
 
Scheme 2.15. Synthesis of 1,3-cyclohexanediol  
  
Having succeeded in executing the proposed reaction, we were interested in 
































useful substrate. Mono deprotection of the product 2.15.3 may not be feasible and we 
were unaware of any methods for the chemoselective deprotection of either TBS or TIPS 
in the presence of the other. So we decided to use the silyl groups of significantly 
different strength in the above reaction, which can be differentiated easily at a later stage. 
We performed the above reaction exactly following the conditions described above 
except by using TMS dithiane instead of TBS dithiane to obtain the cyclohexane 2.16.1 
in 69% yield (Scheme 2.16).  
 Raney nickel-mediated reduction of 2.16.1 in refluxing ethanol led to the loss of 
the TMS group as well as removal of the dithiane resulting in cyclohexane-1,3-diol  
2.16.2 in 67% yield. Deprotection of the dithiane in 2.16.1 by using mercuric chloride in 
aqueous acetonitrile resulted in the keto product 2.16.4 in 77% yield.  
 
 
Scheme 2.16. Deprotection of dithiane 
 
Following the same route as described above for (S,S)-2.16.2, (R,R)-2.16.2 was prepared 

































Scheme 2.17. Synthesis of (1S,3S)-cyclohexane-1,3-diol 
 
Synthesis of 3,5-dihydroxypiperidine 
 Synthesis of 3,5-dihydroxypiperidine using the addition of a primary amine to 
dichlorodiol 2.14.1 was attempted under different conditions (Table 2.1). However, the 
reaction was very slow and took 48 h to undergo completion with the best yield of 41% 
(Table 2.1, entry 1–4). To facilitate this reaction we converted the dichloro diol (R,R)-
2.14.1 to diiodo derivative (R,R)-2.18.1 in 92% yield by treatment with sodium iodide in 
acetone. Treatment of the diiodo compound (R,R)-2.18.1 with benzyl amine in 
acetonitrile at 80 ºC produced the desired piperidine (R,R)-2.18.2 in 66% yield. Switching 
the solvent to ethanol improved the yields significantly, resulting in 85% yield of the 
piperidine product. Under microwave heating conditions and using ethanol as solvent the 
reaction was completed in 2 h, providing the piperidine product (R,R)-2.18.2 in 88% 
yield. Treatment of (R,R)-2.18.2 with 1M TBAF in THF provided the dihydroxy 




































Scheme 2.18. Synthesis of (3R,5R)-1-benzylpiperidine-3,5-diol 
 
Table 2.1. Optimization of conditions for the synthesis of 
3,5-dihydroxy piperidines 
entry X conditions yield 
1 Cl 2 eq Hunig’s base, THF, reflux, 48 h 17% 
2 Cl 2 eq Hunig’s base, ACN, 80 ºC, 48 h 41% 
3 Cl 2 eq Hunig’s base, ACN, n-Bu4NI, 50 ºC, 48 h 10% 
4 Cl 2 eq Hunig’s base, DMF, n-Bu4NI, 80 ºC, 48 h 39% 
5 I 2 eq Hunig’s base, ACN, 80 ºC, 24 h 66% 
6 I 2 eq Hunig’s base, EtOH, 100 ºC, 24 h 85% 
7 I Hunig’s base, 2 eq EtOH, 100 ºC, µW, 2 h 88% 
 
By using the diiodo diol (S,S)-2.18.1 as starting material, N-benzylated-3,5 
dihydroxylated piperidine (S,S)-2.18.2 was obtained in four steps (Scheme 2.19). The 
TIPS cleavage using TBAF provided (S,S)-2.18.3 in 94% yield and er > 99:1. 
 
 










































3,5-Dihydroxy tetrahydrothiopyran 2.20.1 was synthesized using sodium sulfide 
as the source of sulfur nucleophile (Scheme 2.20). After optimization (Table 2.2) we 
obtained 3,5-disubstituted tetrahydrothiopyran (R,R)-2.20.1 in 88% yield (er = 97:3, 
determined by chiral GC) by using 10 eq of aq sodium sulfide and diiodo diol (R,R)-
2.18.1, under refluxing conditions in ethanol in 24 h (Table 2.2). Under microwave 
conditions the reaction was completed in 2 h providing similar yields as obtained under 
the standard heating conditions. Subsequent deprotection of the silyl group provided 
(R,R)-2.20.2 in 92% yield.  
 
 
Scheme 2.20. Synthesis of (R,R)-3,5-dihydroxy  
tetrahydrothiopyran 
 
Table 2.2. Optimization of the thiopyran ring formation 
 
entry conditions yield 
1 1 eq Na2S, CH3CN, 24 h 23% 
2 2 eq Na2S, CH3CN, 24 h 41% 
 3 10 eq Na2S, EtOH, reflux, 16 h 88% 
4 10 eq Na2S, EtOH, µW, 100 ºC, 2 h 90% 
 
Starting with diiododiol (S,S)-2.18.1, using identical route as described for the synthesis 













yield and er 97:3 (Scheme 2.21). Treatment of (S,S)-2.20.1 with TBAF provided diol 




Scheme 2.21. Synthesis of (S,S)-3,5-dihydroxy  
tetrahydrothiopyran 
 
 In summary, we have developed a concise stereodivergent approach for the 
synthesis of enantioenriched six-membered 3,5-disubstituted carbo- and heterocycles. As 
compared to the previously reported routes to access these compounds, the present 
approach is much shorter and can provide trans-cyclohexane-1,3-diols in four steps and 
the piperidine diols in three steps from the previously reported dichlorodiol. We also 
extended our approach toward the synthesis of enantioenriched dihydroxy 
tetrahydrothiopyran ring, which are being increasingly represented in newly discovered 
















Development of Libraries Based on 5- and 6-Membered Cyclic 1,3-Diols 
 
3.1. Introduction 
 The development of small-molecule libraries for biological screening remains an 
important area of interest for drug and probe discovery.74  Although target-oriented 
synthesis75 of small molecules plays an important role to identify hits, it remains short of 
probing novel and complex targets.  Many disorders, such as cancer and 
neurodegenerative diseases, are often associated with complex interactions involving 
transcription factors, protein-protein interactions and DNA–protein interactions.76 Such 
targets have been considered “undruggable” due to the challenges they pose to a typical 
drug discovery program.77 In this context, screening of small-molecule collections to 
identify hits that can perturb the function of gene products, has proved an effective way 
of understanding complex biological processes, and allows for discovering new targets 
and compounds with potential therapeutic applications.78, However, to ensure the success 
of these efforts, it is essential that such molecule collections are diverse and contain 
compounds of suitable structural complexity.79 Diversity is important, as in phenotypic 
screens (cell-based or organism-based) there is no single particular target, any one of the 
cell’s or organism’s entire pool of macromolecules could be an eventual target.80,81 
Complexity is another important component as many biological processes, particularly 
those based on protein–protein interactions are known to be disrupted by structurally 




3.2. Diversity-oriented synthesis based on natural products 
 Natural products have long inspired drug discovery and chemical biology. For 
example, natural products such as camptothecins, taxoids and vinca alkaloids have been 
used in clinic.82 Also, natural products such as actinonin,83 geldanamycin,84 trapoxin85 
and rapamycin86 have been important tools to study and discover new therapeutic targets 
(Figure 3.1). Natural product isolation is an important means of providing access to novel 
natural product structures. Engineered biosynthesis has been emerging as an important 
technological means to access new natural products for testing purposes. In the similar 
context, diversity-oriented synthesis of natural product-inspired libraries has emerged as 
a very successful strategy to access skeletally diverse, structurally complex, 
stereochemically rich, and densely functionalized molecules. Such libraries have resulted 
in the discovery of new biologically active molecules.   
 
 
Figure 3.1. Examples of natural products having applications  





















































3.3. Design strategies for DOS of natural product-like libraries   
 Shang and Tan have reviewed the design strategies of natural product-like 
libraries, separating them into three broad categories: (1) libraries based upon the 
individual natural products; (2) libraries based upon a common substructure found across 
a class of natural products; and (3) libraries that mimic the structural features of natural 
products in a more general sense.87 
 
3.3.1. Libraries based on core scaffolds of individual natural products  
 Such libraries have been initially targeted to optimize the parent activity of the 
natural product.88 Natural product cores can also be used as biologically validated 
frameworks that can be decorated with diverse functional groups. Such libraries may 
have the potential to address biological targets different than the one targeted by the 
parent natural product.82 For example, Waldman and coworkers developed a 147 
compound butenolide library based on the natural product dysidiolide [a cell division 
cycle 25 homolog A (Cdc25A) inhibitor]. From this collection they identified several 
sub-micromolar inhibitors of acetylcholine esterase (AChE), 11-β-hydroxysteroid 




Figure 3.2. Dysidiolide inspired library of butenolide derivatives89 
 
Another example such an approach was reported by the Schreiber group.91 They 
constructed a library of spirooxindoles based on spirotryprostatin B, a mammalian cell-
cycle inhibitor. Several enhancers of latrunculin B (an actin polymerization inhibitor) 
have been identified from this collection (Figure 3.3).  
 
 
























































3.3.2. Libraries based on common substructures from classes of natural products 
 Libraries based on the specific substructures, generally found within a class of 
natural products have increased potential to generate structural diversity that may address 
a wide range of biological targets. An early example of such an effort was reported by the 
Nicolaou group. They constructed a 10,000 compound library based on 2,2-
dimethylbenzopyrans, a structural motif found in numerous natural products with diverse 
activities.92–94 Screening of this library in different assays led to the discovery of 
compounds showing wide range of activities (Figure 3.4). An inhibitor of NADH 
ubiquinone oxidoreductase was identified.95 Also, they have identified a compound active 
against six different MRSA strains, which is equipotent to vancomycin.95 Screening 
against a reporter gene assay led to the identification of novel non-steroidal agonists of 
the farnesoid X reporter.96  
 
 
Figure 3.4. Library comprising 2,2-dimethylbenzopyrans as structural motif93,94,  
 
3.2.3. Libraries with general structural characteristics of natural products  
 This approach utilizes the structural features of the natural products in a general 
sense and has no direct connection to specific structures from natural products. However 






















identify truly novel pharmacophores that are considered undruggable. For example 
Schreiber and coworkers developed 1,3-dioxane-based libraries in this category.97,98 They 
have identified uretupamine B, a functional-selective inhibitor of the yeast nutrient 
signaling protein Ure2p. Diversifying 1,3-dioxane core with the metalloprotein binding 
side chains led to the discovery of the inhibitors of the histone deacetylase family 
(HDAC). They have identified two selective histone deacetylase, tubacin, a selective 
inhibitor of HDAC6, which is a α-tubulin deacetylase, and histacin, that have true histone 
deacetylase activity and does not inhibit HDAC6 (Figure 3.5). These studies led to the 
identification of HDAC6 as a novel potential antimetastatic and antiangiogenic 
therapeutic target.  
 
 



































Boger and coworkers developed structurally diverse libraries using amide-bond-forming 
reactions, resulting in peptide like collection of compounds.99 Several protein-protein 
interaction inhibitors have been identified from these libraries including antagonists of 
the MMP2-avb3,100 Epo-EpoR,101 Lef-1–β-catenin,102 and Myc-Max103,104 protein–





















































3.3. Small-molecule libraries of stereochemically diverse compounds 
 Generally, the focus of the above-cited approaches has been to achieve diversity 
through functional group variation among the members of the library. An alternative 
approach of varying functional group presentation is through extensive stereochemical 
diversification. Though constitutionally identical, the stereoisomeric compounds have 
topographical differences, resulting in distinct interactions with the macromolecular 
targets. The molecules generated by such approach are designed to explore the 
conformational space through geometric variation of the ligand scaffold. Though natural 
product-inspired libraries are often skeletally and stereochemically diverse however there 
are few examples in literature where an exhaustive stereochemical diversification has 
been used around a scaffold to produce a collection of small-molecules of diverse 
topology. An early example was reported by Paterson and co-workers in 1992.105  They 
generated a library of 32 polyketide stereopentads by exhaustive stereochemical 
diversification. In 1999, Schreiber group reported conformationally diverse macrocyclic 




Figure 3.7. Conformationally diverse lactones105  
 
An excellent example of a library of spatially separated compounds was described by the 























target diverse aspartyl proteases. The screening of this library resulted in the 
identification of potent cathepsin D inhibitors (Figure 3.8).107  
 
 
Figure 3.8. Examples from Ellman’s library of spatially separated compounds 
determining cathepsin D inhibitory activity107 
 
In 2000, the Verdine group reported a modular approach towards the synthesis of 
stereodiversified natural product-like libraries.108,109 They generated the libraries of all 
the possible stereoisomers of the cis-1,4-enediol and cis-1,5-enediols via silyl-tethered 






























































3.4. Results and Discussion 
 As discussed in the introduction above that the development of small-molecule 
libraries is an important area of interest to reveal novel biological targets of therapeutic 
relevance. Natural product structures have been motivation as well inspiration to design 
such libraries. Various strategies have been used in this regard as discussed in the 
introduction. However, there are not many stereochemically diverse libraries reported in 
the literature.  
 In the present work, we describe the development of a small-molecule library of 
stereochemically diverse compounds by integrating structural features of prostaglandin 
natural products, a highly important and physiologically relevant class of natural 
products, and α-amino acids that are natural chiral building blocks.  
 
3.4.1. Library Design  
We recognized that the stereo elements on a small five-membered carbocycle, 2-
cyclopentene-1,4-diol can be utilized to target stereochemically diverse compounds. This 
idea was enabled by easy access to either of the enantiomer of 2-cyclopentene- trans-1,4-
diol on gram scale by the recently developed approach in our laboratory (discussed in 
Chapter 1). Also, it was easily conceivable that the cis isomers of the diols could be 
synthesized via Mitsunobu inversion of one of the alcohol stereocenter in 2-
cyclopentene- trans-1,4-diol. The presence of alcohol functionality provides an 




Figure 3.10. Integrating prostaglandin  
core with amino acids 
 
One could readily append side chains by either an ester or a carbamate linkage; however 
we chose to avoid esters considering the high hydrolytic nature of this group under 
biological conditions. The carbamate linkage was chosen due to ease of synthesis and 
because carbamates have been effectively used in both drug molecules and screening 
libraries.  Natural amino acids were chosen as the side chain derivatizing partners. Amino 
acids are unarguably biologically relevant, and are economical means of adding 
complexity because of the presence of a chiral center, and provide diversity by means of 
both polar and non-polar side chains. The presence of carboxylic acid in the side chain 
adds another feature of prostaglandins that have carboxylic acid side chains. We chose 
ten different amino acids having significantly different side chains for the library 
particularly, tryptophan having a heterocyclic indolyl side chain; amino acids with polar 
side chains serine, asparagine, glutamic acid, non-polar side chains alanine, leucine, 
methionine, phenylalanine, and the cyclic amino acid proline were employed.  
 
3.4.1. Library Plan (Figure 3.11) 
 For the cyclopentenediol library, we decided to use all four isomers of the 
monoprotected 2-cyclopentene-1,4-diol. As depicted in Figure 3.11, we planned to 















L-asparagine at the first step, leading to four scaffolds of amino acid derived alcohols. 
Each scaffold would then be derived with six different amino acids, leading to 24 
compounds. Ultimately using all of the four isomers of 2-cyclopentene-1,4-diol, a 96 
compound library was planned.  
 
 
Figure 3.11. Library plan 
 
3.4.2. Library synthesis  
 To accomplish the planned library, each of the isomeric 2-cyclopentene-1,3-diol 
was prepared in excess of 3–4 g quantities using the synthetic route discussed in Chapter 
1. Thus, starting with the commercially available acetyl acetone, dichloro compound 
1.21.2 was prepared at 65 g scale and was preserved as a copper salt 1.21.3 (Scheme 3.1). 
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 67 
Copper salt 1.21.3 was hydrolyzed with aqueous sulfuric acid to obtain dichlorodione 
1.21.2 just prior to the Noyori hydrogenation step (Scheme 3.2). 
 
 
Scheme 3.1. Synthesis of dichlorodione  
 
Following Rychnovski’s procedure, asymmetric reduction of 22 g of 1.21.2 in a Parr 
hydrogenator at 1250 psi provided 8.7 g of the enantioenriched (R,R)-dichlorodiol 1.21.5 
after recrystallization from hexane–DCM.110 Switching the catalyst to (R)-BINAP-
Ru(II)Cl2 provided the (S,S)-1.21.5 following the same procedure (Scheme 3.2).  
 
 
Scheme 3.2. Synthesis of dichlorodiols 
 
In the next step, dichlorodiol 1.21.5 was subjected to the Corey-Chaykovski 
homologation.34 However, the amount of trimethylsulfonium salt and the volume of n-
BuLi required for this step limited the scalability of this step. So Corey-Chaykovski 
homologation of 1.21.5 was performed in batches at 4 g scale to accumulate 10 g of diene 
diol (R,R)-1.21.2 (Scheme 3.3). Monosilylation of dienediol (R,R)-1.21.2  followed by 






































1.26.1. Cis diol (S,R)-1.26.1 was obtained in two steps via Mitsunobu reaction of   (R,R)-
1.26.1 with 4-nitrobenzoic acid followed by basic hydrolysis of the resulting benzoate 
ester. Both (R,R)-1.26.1 and (S,R)-1.26.1 were prepared on 4 g scale.  
 
Scheme 3.3. Synthesis of diols (R,R)-1.25.1 and (S,R)-1.25.1 
 
Following the same process as described above, (S,S)-1.26.1 and (R,S)-1.26.1 were 




Scheme 3.4. Synthesis of diols (S,S)-1.26.1 and (R,S)-1.26.1 
 
The alcohol (R,R)-1.26.1 was treated with triphosgene and pyridine in an attempt to 
synthesize chloroformate, however various attempts towards this goal were not 
successful. Switching to another carbonylating reagent, 4-nitrophenyl chloroformate 
provided the desired product only in 10% yield. The majority of the starting material was 
isolated in this case. Finally, we considered using n-butyl lithium under low temperature 
conditions to deprotonate the alcohol and quenching the anion with the excess of 
carbonylating reagent.  Following this method, the resulting carbonate 3.5.1 was isolated 
in 77% yield.  
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Scheme 3.5. Synthesis of alcohol carbonate 
 
Using the conditions optimized above, the isomeric alcohols 1.26.1 were converted to 
carbonates on a scale of 2.5 to 3.0 g (Scheme 3.6).  
 
 
Scheme 3.6. Synthesis of carbonates  
 
Reaction of carbonate (R,R)-3.5.1 with amino acid ester in the presence of catalytic 
amount of DMAP in THF at 100 ºC formed the amino acid carbamates in 72–82% yield 



















n-BuLi, -78 ºC                




























Scheme 3.7. Synthesis of silyl monocarbamates  
 
3.4.3. Optimization of library method  
Silyl carbamate (S,R,R)-3.7.1 subjected to TIPS deprotection using TBAF and the 
resulting crude alcohol was treated with amino acid isocyanate. However the reaction of 
isocyanate with alcohol was very slow in refluxing toluene for 48 h, leaving a significant 
amount of starting material (Scheme 3.8). Ultimately, reacting alcohols with excess of 
neat isocyanates (3 equiv) in the presence of catalytic amount of N,N-




































































































































Scheme 3.8. Optimization of method for biscarbamate synthesis 
 
The above-optimized conditions were used for the synthesis of a validation library of bis 
carbamates. Alcohols 3.7.1–3.7.4 were reacted with six different amino acid isocyantes in 
two-dram vials on a 24-well heating block (Scheme 3.9). The reaction mixture was 
cooled to room temperature and was dissolved in dichloromethane. Each of the reaction 
mixture was transferred to reaction tubes charged with tris-(2-aminoethyl)-amine, 
polymer bound resin) on a 24-well (4x6) Mini-BlockTM reaction array. The contents were 
filtered through the tris-(2-aminoethyl)-amine resin and the resin was washed with 
dichloromethane. The reaction contents were collected in collection tubes and the solvent 
was evaporated under by purging nitrogen gas. The crude reaction mixtures were 
subjected to mass-directed automated purification resulting in 18 biscarbamates in 4–62 
mg quantities and purities >90%. The purification results of the 24 compounds are listed 







Et3N, THF,  24 h, rt
DMAP, THF, reflux, 24 h
toluene, DMAP, reflux, 48 h

































































Table 3.1. Biscarbamate Librarya 




1 (S,R,R,S)-3.9.7 3-indolyl-ylmethyl PhCH2 24 100 
2 (S,R,R,S)-3.9.8 3-indolyl-ylmethyl tBuOCH2 62 98 
3 (S,R,R,S)-3.9.9 3-indolyl-ylmethyl (CH3)2CHCH2 34 94 
4 (S,R,R,S)-3.9.10 3-indolyl-ylmethyl CH3SCH2CH2 25 79 
5 (S,R,R,S)-3.9.11 3-indolyl-ylmethyl tBuO2CCH2CH2 54 99 
6 (S,R,R,S)-3.9.12 3-indolyl-ylmethyl p-tBuOPhCH2  25 92 
7 (S,R,R,S)-3.9.13 H2NCOCH2 PhCH2 27  100 
8 (S,R,R,S)-3.9.14 H2NCOCH2 tBuOCH2 44 98 
9 (S,R,R,S)-3.9.15 H2NCOCH2 (CH3)2CHCH2 39 39 
10 (S,R,R,S)-3.9.16 H2NCOCH2 CH3SCH2CH2 26  100 
11 (S,R,R,S)-3.9.17 H2NCOCH2 tBuO2CCH2CH2 66 98 
12 (S,R,R,S)-3.9.18 H2NCOCH2 p-tBuOPhCH2 22 39 
13 (S,R,R,S)-3.9.19 L-proline PhCH2 34 100 
14 (S,R,R,S)-3.9.20 L-proline tBuOCH2 10 98 
15 (S,R,R,S)-3.9.21 L-proline (CH3)2CHCH2 18 97 
16 (S,R,R,S)-3.9.22 L-proline CH3SCH2CH2 71 100 
17 (S,R,R,S)-3.9.23 L-proline tBuO2CCH2CH2 25 56 
18 (S,R,R,S)-3.9.24 L-proline p-tBuOPhCH2 34 98 
19 (S,R,R,S)-3.9.25 CH3 PhCH2 5 78 
20 (S,R,R,S)-3.9.26 CH3 tBuOCH2 27 96 
21 (S,R,R,S)-3.9.27 CH3 (CH3)2CHCH2 29 41 
22 (S,R,R,S)-3.9.28 CH3 CH3SCH2CH2 39 98 
23 (S,R,R,S)-3.9.29 CH3 tBuO2CCH2CH2 33 92 
24 (S,R,R,S)-3.9.30 CH3 p-tBuOPhCH2 38 65 
a Please see experimental section for the purification method details. 
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Following the library method optimized above, the silyl carbamates (S,S,R)-, (S,S,S)- and 





Scheme 3.10. Synthesis of 72-membered biscarbamate library 
 
 
Ten crude reaction mixtures were randomly chosen from this pool, were purified by 
column chromatography and the structures were confirmed by NMR and mass analysis. 
The rest of the compounds were submitted for mass-directed purification. However the 
analysis by mass did not respond well unlike the case of validation library (Note: the 
Agilent Purification system which was originally used for the validation library by 
Patrick Porubsky, was out of order and the current set of compounds was processed by 
Ben Nuenswander over a different system). Various attempts were made by analyzing the 
individual fractions by proton nmr to detect the desired compound fractions however it 













































individual crude reaction mixture.  The crude products could not be recovered because of 
the numerous fractions generated in the purification process.  
 
3.4.4. Library of C2-symmetric biscarbamates 
 With an objective to increase the diversity, we also targeted the six-membered bis 
carbamates by taking advantage of the method described in Chapter 2. In this part of the 
project, we targeted a library of 24 C2-symmetric compounds based on the five and six-
membered carbo- and heterocyclic diols (Figure 3.12).  
 
Figure 3.12. Six-membered C2-symmetric biscarbamates 
 
To accomplish this goal, we scaled-up each of the trans-diols 2.16.3, 2.18.3, 2.20.2 and 
3.12.1 to 200 mg scale. Mono TIPS protection of dichloro diol (S,S)-1.21.5 provided  diol 
(S,S)-2.14.1 that was treated with powdered potassium hydroxide to form epoxide (S,S)-
2.14.2. Epoxide opening with lithiated 2-TMS-dithiane followed by intramolecular 
cyclization via SN2 displacement of chloro led to the production of cyclohexane product 
(S,S)-2.16.3. Reductive removal of dithiane using Raney Ni followed by TIPS cleavage 




























































Scheme 3.11. Synthesis of (S,S)-cyclohexane-1,3-diol 
 
Mono TIPS protected dichlorodiol was converted to diiodo diol (S,S)-2.18.1 that was 
converted to dihydroxy piperididne (S,S)-2.18.3 in two steps (Scheme 3.12). Treatment of 
diiododiol with sodium sulfide in ethanol followed by TIPS cleavage with TBAF 
provided diol (S,S)-2.20.2 in 88% yield. 
 
 
Scheme 3.12. Synthesis of heterocyclic diols  
 
Five-membered diol (S,S)-3.12.1 was prepared in 71% yield by subjecting diene diol 



















































1. Na2S, EtOH 







Scheme 3.13. Synthesis of (S,S)-2-cyclopentene-1,3-diol 
 
The (S,S)-diols 2.16.3, 2.18.3, 2.20.2 and 3.13.1 were subjected to react with the six 
different amino acid isocyanates in 2 mL vials placed in a 24-well heating block for four 
hours at 100 ºC (Scheme 3.13). A random subset of five of the resulting reaction mixtures 




Scheme 3.13. Synthesis of library of five- and six-membered C2-symmetric 
biscarbamates 
 
In summary, we targeted 120 compound library of biscarbamates using  five- and 
six-membered cyclic 1,3-diols. Twenty stereochemically diverse scaffolds were 
successfully prepared on 150–300 mg scale in enantiomerically enriched form. A suitable 
method was optimized for the library synthesis using Mini-BlockTM platform and 
purification results showed promising results during validation, producing 18 compounds 
on an average of 35 mg quantity and purities >90%. This library effort was enabled by 
developing synthetic approaches to access enantioenriched five and six-membered carbo- 
Cl Cl
OH OH OH OH
80–82% 71%
(S,S)-1.20.4 (S,S)-1.20.1


























X = CH2, (S,S)-2.16.3
X = NCH2Ph  (S,S)-2.18.3

















and heterocyclic diols. With an optimized method in hand and the synthetic access to the 
enantiopure building blocks, a larger library campaign could be enabled if supported by a 
suitable analytical and purification system. We believe that stereochemical diversity of 
such a library collection may provide varying topographical features to these molecules 
and the appended amino acid side chains will enable to probe the important interactions 












General Methods. All reactions were carried out in oven- or flame-dried glassware 
under argon atmosphere using standard gas-tight syringes, cannulas, and septa. Et2O, 
THF and CH2Cl2 were purified by passage through an alumina based commercial 
purification system (Solv-Tek). Column chromatography was performed with Sorbent 
Technologies (30930M-25, Silica Gel 60A, 40-63 µm) and thin layer chromatography 
was performed on silica gel 60F254 plates (EM-5717, Merck). 1H and 13C NMR spectra 
were recorded in CDCl3 on a Bruker AV-400 spectrometer and calibrated to the solvent 
peak.  High-resolution mass spectra (HRMS) were recorded on Waters LCT premier 
Micromass from MS Technologies. Observed optical rotations at 589 nm, were measured 
using AUTOPOL IV Model automatic polarimeter. IR spectra were recorded on 
Shimadzu FTIR-8400S instrument.  The er values of the compounds (R)-1.20.3, (S)-
1.20.3, (R)-1.4.3, (R)-1.4.1, (R)-1.20.4, (S)-1.20.4, (R,R)-2.16.2, (S,S)-2.16.2, (R,R)-
2.20.1 and (S,S)-2.20.1 were determined by gas chromatography using a 5975CVL MSD 
triple-axis detector. The er value of the compounds (R)-1.27.1, (R)-2.18.3 and (S)-2.18.3 
were determined by chiral HPLC on an IC column with a 996 UV detector. Preparative 
reverse-phase HPLC was performed on a Waters 2767 preparative system [UV (214 nm, 
2996 PAD) and mass detection (Micromass ZQ)], using a Waters X-Bridge C18 column 
(19 x 150, 19 x 10 mm guard column), and water/acetonitrile as eluent with 20% increase 
in gradient over 4 min at a flow rate of 20 mL/min. 
 
Known compounds: The compounds 1.20.1, (R,R)-1.20.4 (S,S)-1.20.4  were prepared 








 (3R,5R)-5-((Triisopropylsilyl)oxy)hepta-1,6-dien-3-ol (1.20.2). To a stirred solution of 
(3R,5R)-hepta-1,6-diene-3,5-diol 1.20.1 (2.7 g, 21.1 mmol) in THF (200 mL) at –78 ºC, 
was added n-BuLi (9.3 mL, 2.5 M in hexanes, 23.2 mmol) dropwise. The solution was 
allowed to stir for 20 min at –78 ºC followed by the slow addition of TIPSCl (4.9 mL, 
23.2 mmol). After 2 h, the reaction was allowed to slowly warm to rt overnight and was 
quenched with saturated NH4Cl(100 mL). The organic phase was washed with saturated 
NH4Cl (3 × 100 mL), brine, dried (Na2SO4), filtered, and concentrated. The crude extract 
was purified by silica gel chromatography (10% EtOAc/hexanes) to afford the product as 
yellow oil (5.4 g, 96%). Rf = 0.73 (20% EtOAc/hexanes); IR (neat) 3423 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 5.94 (ddd, J = 17.1, 10.5, 5.9 Hz, 1H), 5.83 (ddd, J = 17.1, 10.4, 5.6 
Hz, 1H), 5.26 (ddd, J = 12.0, 1.5, 1.5 Hz, 1H), 5.22 (ddd, J = 11.8, 1.4, 1.4 Hz, 1H), 5.14 
(ddd, J = 10.5, 1.4, 1.4 Hz, 1H), 5.09 (ddd, J = 10.5, 1.5, 1.5 Hz, 1H), 4.62–4.56 (m, 1H), 
4.47–4.37 (m, 1H), 3.59 (bs, 1H), 1.87 (ddd, J = 14.0, 9.6, 4.4 Hz, 1H), 1.68 (ddd, J = 
14.4, 4.4, 2.8 Hz, 1H), 1.03–1.10 (m, 21H); 13C NMR (100.6 MHz, CDCl3) δ 140.9, 
140.0, 114.9, 114.0, 73.2, 69.6, 43.2, 18.01, 17.99, 12.2; m/z (ESI+) found [M+H]+ 








(3R,5R)-5-((tert-Butyldimethylsilyl)oxy)hepta-1,6-dien-3-ol (R,R-1.23.1). To a stirred 
solution of (3R,5R)-hepta-1,6-diene-3,5-diol (150 mg, 1.17 mmol) and tert-
butyldimethylsilyltrifluoromethane sulfonate (1.17 mmol, 0.269 mL) in THF (20 mL) at 
–78 ºC, 2,6-lutidine (1.36 mL, 11.7 mmol) was added dropwise via syringe. The solution 
was allowed to stir for 2 h at  –78 ºC. The reaction was quenched with aq NH4Cl (20 mL) 
and extracted with ethyl acetate (3 × 30 mL). The organic phase was washed with brine, 
dried (Na2SO4), filtered, and concentrated. The crude product was purified by silica gel 
chromatography (10% EtOAc in hexane) to afford the desired product as colorless oil 
(260 mg, 92%). Rf = 0.62 (20% EtOAc/hexanes); IR (neat) 3419 cm-1; 1H NMR (400 
MHz, CDCl3) δ 5.91–5.81 (m, 2H), 5.26 (dt, J = 4.0, 1.6 Hz, 1H), 5.22 (dt, J = 3.6 Hz, 
1H), 5.09 (ddt, J = 20.0, 10.4, 1.6 Hz, 2H), 4.51–4.47 (m, 1H), 4.41–4.36 (m, 1H), 3.26 
(d, J = 2.8 Hz, 1H), 1.77–1.65 (m, 2H), 0.91 (s, 9H), 0.08 (d, J = 12.0 Hz, 6H). 13C NMR 
(101 MHz, CDCl3) δ 141.0, 140.3, 114.8, 114.1, 72.4, 69.7, 43.4, 25.9, 18.2, -4.3, -4.9; 






(3R,5R)-5-Hydroxyhepta-1,6-dien-3-yl acetate (1.24.1). To a stirred solution of 
(3R,5R)-hepta-1,6-diene-3,5-diol (200 mg, 1.56 mmol) in acetonitrile (15 mL), triethyl 
orthoacetate (0.43 mL, 2.34 mmol) and p-toluenesulfonic acid (20 mg) were added. The 
reaction mixture was stirred at rt for 1h and a mixture of hydrochloric acid in methanol 
(0.2 mL HCl in 1 mL MeOH) was added to it. The stirring was continued for another 3 h 
AcO OH
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at rt. The reaction was quenched with saturated NaHCO3 solution (10 mL) and was 
extracted with ethyl acetate (3 × 20 mL). The combined organic layer was washed with 
brine, dried (Na2SO4) and concentrated under vacuum. Purification via column 
chromatography provided the desired product as colorless oil (213 mg, 82%). Rf = 0.52 
(20% EtOAc/hexanes); IR (neat) 3426, 1717 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.87–
5.75 (m, 2H), 5.48–5.42 (m, 1H), 5.23 (d, J = 17.2 Hz, 2H), 5.10 (dd, J = 23.2, 10.4 Hz, 
2H), 4.08 (bs, 1H), 2.73 (s, 1H), 2.06 (s, 3H), 1.85–1.64 (m, 2H); 13C NMR (101 MHz, 
CDCl3) δ 171.1, 140.2, 136.3, 116.6, 114.8, 71.8, 68.7, 42.0, 21.2; m/z (ESI+) found 





 (3R,5R)-5-((4-Methoxybenzyl)oxy)hepta-1,6-dien-3-ol (1.25.1). To a 100 mL round 
bottom flask containing sodium hydride (83 mg of 50% dispersion, 1.72 mmol, 
prewashed with hexane) under argon, a solution of (3R,5R)-hepta-1,6-diene-3,5-diol (200 
mg, 1.56 mmol) in THF (20 mL) was transferred via syringe at 0 ºC. The solution was 
stirred for 30 min. at rt and again cooled to 0 ºC. A solution of 4-methyoxybenzyl 
chloride (366 mg in 2 mL of THF, 2.34 mmol) was added via syringe and the reaction 
mixture was stirred at rt for overnight.   The reaction was quenched with saturated NH4Cl 
solution (10 mL) and was extracted with ethyl acetate (3 × 20 mL). The combined 
organic layer was washed with brine, dried (Na2SO4) and concentrated under vacuum. 
Purification via column chromatography provided the desired product as colorless oil 
PMBO OH
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(236 mg, 66%). Rf = 0.55 (20% EtOAc/hexanes); IR (neat) 3430 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.29 (d, J = 8.2 Hz, 2H), 7.27 (d, J = 8.2 Hz, 2H), 5.93–5.79 (m, 2H), 
5.32–5.26 (m, 3H), 5.12 (ddd, J = 10.5, 1.6, 1.6 Hz, 1H), 4.56 (d, J = 11.2 Hz, 1H), 4.47–
4.37 (m, 1H), 4.30 (d, J = 11.2 Hz, 1H), 4.16–4.09 (m, 1H), 3.82 (s, 3H), 2.97 (m, 1H), 
1.90 (ddd, J = 14.4, 8.4, 3.2 Hz, 1H), 1.73 (ddd, J = 14.8, 8.0, 3.6 Hz, 1H). 13C NMR 
(101 MHz, CDCl3) δ 159.3, 140.8, 138.1, 130.2, 129.6, 117.3, 114.1, 113.9, 77.7, 70.2, 
69.8, 55.4, 41.8; m/z (ESI+) found [M+H]+ 249.1490, C15H21O3 requires 249.1491; 
[!]!!".! +139 (c 6.4, DCM). 
 
General procedure for the synthesis of cyclopentenols (1.26.1, 1.4.5, 1.3.3 and 1.26.2) 
via ring-closing metathesis. A solution of starting diene in DCM (0.02 M) was purged 
with argon for 5 min and Grubbs-I catalyst (3 mol%) was added to it under argon. The 
reaction mixture was stirred for 1 h at 50 ºC and quenched with DMSO (1 mL). The 
solution was stirred under air for 5 min and concentrated. The solvent was evaporated 
and the crude reaction mixture was purified by silica gel column chromatography to 






 (1R,4R)-4-((Triisopropylsilyl)oxy)cyclopent-2-enol (1.26.1). Following above general 
procedure diene 1.20.1 (5.00 g, 17.6 mmol) provided cyclopentenol 1.26.1 (4.14 g, 92%) 
as a colorless oil. Rf = 0.41 (20% EtOAc/hexanes); IR (neat) 3322 cm-1; 1H NMR (400 
MHz, CDCl3) δ 6.04–5.80 (m, 2H), 5.24–5.06 (m, 1H), 4.98 (d, J = 1.9 Hz, 1H), 2.24–
1.96 (m, 3H), 1.17–0.91 (m, 21H); 13C NMR (101 MHz, CDCl3) δ 138.5, 135.5, 76.6, 
76.2, 44.8, 18.1, 18.0, 12.2; m/z (ESI+) found [M+H]+ 257.1933, C14H29O2Si requires 





 (1R,4R)-4-((tert-Butyldimethylsilyl)oxy)cyclopent-2-enol (1.4.5). Following above 
general procedure diene 1.23.1 (200 mg, 17.6 mmol) provided cyclopentenol 1.4.5 (156 
mg, 88%) as a colorless oil. Rf = 0.44 (20% EtOAc/hexanes); IR (neat) 3327; 1H NMR 
(400 MHz, CDCl3) δ 5.95–5.90 (m, 2H), 5.08–5.05 (m, 1H), 5.03–4.97 (m, 1H), 2.08–
1.97 (m, 2H), 1.74 (s, 1H), 0.88 (s, 9H), 0.07 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 
138.5, 135.6, 76.7, 76.3, 44.6, 26.0, 18.3, –4.5; m/z (ESI+) found [M+H]+ 215.1465, 










(1R,4R)-4-Hydroxycyclopent-2-en-1-yl acetate (1.3.3). Following above general 
procedure diene 1.24.1  (200 mg, 1.17 mmol) provided cyclopentenol 1.3.3 (147 mg, 
88%) as a colorless oil. IR (neat) 3374, 1723 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.12–
6.06 (m, 1H), 6.01–5.95 (m, 1H), 5.81–5.74 (m, 1H), 5.04–4.97 (m, 1H), 2.49 (br s, 1H), 
2.17 (ddd, J = 14.8, 6.8, 2.8 Hz, 1H), 2.06 (ddd, J = 14.8, 7.2, 3.6 Hz, 1H), 2.00 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 171.2, 139.9, 132.8, 79.1, 75.8, 40.6, 21.2; m/z (ESI+) 
found [M+H]+ 143.0703, C7H11O3 requires 143.0708; [!]!!".! +227 (c 4.9, DCM). 
 
 
(1R,4R)-4-((4-Methoxybenzyl)oxy)cyclopent-2-enol (1.26.2). Following above general 
procedure diene 1.25.1 (200 mg, 0.81 mmol) provided cyclopentenol 1.26.2 (159 mg, 
89%) as a colorless oil. Rf = 0.40 (30% EtOAc/hexanes); IR (neat) 3364 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.31–7.26 (m, 2H), 6.93–6.87 (m, 2H), 6.12–6.03 (m, 2H), 5.08–
5.00 (m, 1H), 4.85–4.78 (m, 1H), 4.50 (d, J = 11.2 Hz, 1H), 4.45 (d, J = 11.2 Hz, 1H), 
3.82 (s, 3H), 2.22 (ddd, J = 14.4, 6.8, 3.2 Hz, 1H), 2.00 (ddd, J = 14.4, 6.8, 2.8 Hz, 1H), 
1.85 (bs, 1H); 13C NMR (101 MHz, CDCl3) δ 159.3, 137.9, 135.1, 130.6, 129.5, 113.9, 
82.9, 70.9, 55.4, 41.1; m/z (ESI+) found [M+H]+ 221.1179, C13H17O3 requires 221.1178; 








General procedure for the synthesis of cyclopentenones (1.20.3, 1.4.3, 1.4.1 and 
1.27.1). To a stirred solution of starting cyclopentenol in DCM (0.1 M) was added 
pyridinium chlorochromate (1.5 equiv) at 0 ºC. The reaction mixture was stirred at rt for 
6 h followed by filtration over Celite. The Celite bed was washed with diethyl ether. The 
combined filtrate was concentrated and purified by silica gel  column chromatography to 





 (R)-4-((Triisopropylsilyl)oxy)cyclopent-2-enone (1.20.3). Following the general 
procedure above, cyclopentenol 1.26.1 (2.00 g, 7.81 mmol) provided cyclopentenone 
1.20.3 (1.86 g, 94%) as a colorless oil. Rf = 0.30 (10% EtOAc/hexanes); IR (neat) 1725 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.49 (dd, J = 5.7, 2.3 Hz, 1H), 6.16 (dd, J = 5.7, 1.2 
Hz, 1H), 5.06 (m, 1H), 2.73 (dd, J = 18.1, 5.9 Hz, 1 H), 2.28 (dd, J = 18.1, 2.2 Hz, 1H), 
1.21–0.98 (m, 3H), 1.06 (d, J = 5.4 Hz, 18H). 13C NMR (101 MHz, CDCl3) δ 206.5, 
163.8, 134.3, 70.9, 45.4, 18.0, 17.9, 12.1; m/z (ESI+) found [M+H]+ 255.1786, 
C14H27O2Si requires 255.1780; [!]!!".! –53 (c 1.05, MeOH). Chiral GC separation: Astec 
Chiraldex B-DM fused silica capillary column, 30m × 0.25 mm × 0.12 mm, temperature 
175 ºC, tR = 37.9 min, tS = 38.7 min, er 97:3. By following the same procedure, 
cyclopentenol (S)-1.26.1 (100 mg, 0.39 mmol) provided cyclopentenone (S)-1.20.3 (93 








 (R)-4-((tert-Butyldimethylsilyl)oxy)cyclopent-2-enone (1.4.3). Following above 
general procedure cyclopentenol 1.4.5 (120 mg, 0.56 mmol) provided cyclopentenone 
1.4.3 (110 mg, 93%) as a colorless oil. Rf = 0.73 (20% EtOAc/hexane); IR (neat) 1722 
cm-1; 1H NMR (400 MHz, CDCl3) δ 7.43 (dd, J = 5.6, 2.4 Hz, 1H), 6.16 (dd, J = 5.6, 1.2 
Hz, 1H), 5.10–4.94 (m, 1H), 2.69 (dd, J = 18.4, 6.0 Hz, 1H), 2.22 (dd, J = 18.0, 2.0 Hz, 
1H), 0.88 (s, 9H), 0.11 (d, J = 4.8 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 206.4, 163.8, 
134.4, 70.8, 44.95, 25.7, 18.1, –4.6 (2); m/z (ESI+) found [M+H]+ 213.1315, C11H21O2Si 
requires 213.1311; [!]!!".! +64 (c 1.6, MeOH). Chiral GC separation: Astec Chiraldex B-
DM fused silica capillary column, 30m × 0.25 mm × 0.12 mm, temperature 175 ºC, tR = 





(R)-4-Oxocyclopent-2-en-1-yl acetate (1.4.1). Following above general procedure 
cyclopentenol 1.3.3 (100 mg, 0.70 mmol) provided cyclopentenone 1.4.1 (91 mg, 92%) 
as a colorless oil. Rf = 0.73 (20% EtOAc/hexanes); IR (neat) 1720 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.55 (dd, J = 5.6, 2.4 Hz, 1H), 6.31 (dd, J = 5.6, 1.2 Hz, 1H), 5.85–5.80 
(m, 1H), 2.80 (dd, J = 18.7, 6.4 Hz, 1H), 2.30 (dd, J = 18.7, 2.0 Hz, 1H), 2.07 (s, 3H). 13C 






[M+H]+ 141.0550, C7H9O3 requires 141.0552; [!]!!".!  +100 (c 1.4, MeOH). Astec 
Chiraldex B-DM fused silica capillary column, 30m × 0.25 mm × 0.12 mm, temperature 





(R)-4-((4-Methoxybenzyl)oxy)cyclopent-2-enone (1.27.1). Following above general 
procedure cyclopentenol 1.26.2 (130 mg, 0.59 mmol) provided cyclopentenone 1.27.1 
(119 mg, 92%) as a colorless oil. Rf = 0.73 (20% EtOAc/hexanes); IR (neat) 1714 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.59 (dd, J = 5.7, 2.3 Hz, 1H), 7.29 (d, J = 8.6 Hz, 2H), 
6.91 (d, J = 8.6 Hz, 2H), 6.24 (dd, J = 5.7, 1.2 Hz, 1H), 4.78–4.72 (m, 1H), 4.56 (dd, J = 
21.3, 11.3 Hz, 2H), 3.81 (s, 3H), 2.67 (dd, J = 18.4, 6.0 Hz, 1H), 2.34 (dd, J = 18.0, 2.0 
Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 205.9, 161.3, 159.5, 135.5, 129.5, 129.5, 113.9, 
76.5, 71.6, 55.2, 41.8; m/z (ESI+) found [M+H]+ 219.1023, C13H15O3 requires 219.1021; 
[!]!!".! +51 (c 3.9, DCM). HPLC (Chiralpak IC column n-hexane/i-PrOH = 90/10, flow 





 (R)-2-Iodo-4-((triisopropylsilyl)oxy)cyclopent-2-enone (1.20.4). To a stirred solution 







followed by dropwise addition of enone 1.20.3 (89 mg, 0.35 mmol) at rt. The reaction 
flask was completely covered with aluminum foil to protect from light. After 24 h, the 
reaction was quenched with aq Na2S2O3 (50 mL). The organic layer was washed with 
brine, dried (Na2SO4), filtered, and concentrated. The resulting oil was purified using 
silica gel chromatography (10% Et2O in hexane) to afford the product as colorless oil (11 
g, 85%). Rf = 0.45 (20% EtOAc/hexanes); IR (neat) 1726 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.84 (d, J = 2.5 Hz, 1H), 6.04 (ddd, J = 6.0, 2.3, 2.3, 1H), 2.90 (dd, J = 18.1, 
6.0 Hz, 1H), 2.40 (dd, J = 18.1, 2.1 Hz, 1H), 1.30–0.87 (m, 3H), 1.07 (d, J = 5.3 Hz, 
18H). 13C NMR (100.6 MHz, CDCl3) δ 200.4, 169.4, 105.0, 72.4, 43.0, 18.0 (2), 12.1; 
m/z (ESI+) found [M+H]+ 381.0750, C14H26IO2Si requires 381.0747; [!]!!".! +23 (c 4.3, 
DCM). Chiral GC separation: Astec Chiraldex B-DM fused silica capillary column, 30m 
× 0.25 mm × 0.12 mm, temperature 175 ºC, tR = 20.99 min, tS = 21.84 min, er 97:3. (S)-





 (1R,2R,4R,5R)-4-((Triisopropylsilyl)oxy)-6-oxabicyclo[3.1.0]hexan-2-ol (1.30.2). To a 
solution of (1R,4R)-4-((triisopropylsilyl)oxy)cyclopent-2-enol (500 mg, 1.95 mmol) in 
DCM (20 mL) m-CPBA (657 mg, 2.93 mmol) was added at 0 ºC and the reaction mixture 
was stirred at rt for 28 h. The reaction mixture was quenched with saturated Na2S2O3 (20 
mL) and extracted with DCM (3 × 50 mL). The combined organic layer was washed with 
saturated NaHCO3, brine and dried (Na2SO4). Evaporation of the solvent followed by 




colorless oil (350 mg, 66%). Rf = 0.37 (10% EtOAc/hexanes); IR (neat) 3320 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 4.50 (td, J = 7.9, 0.9 Hz, 1H), 4.42 (d, J = 5.3 Hz, 1H), 3.57–
3.51 (m, 1H), 3.43–3.36 (m, 1H), 2.30 (m, 1H), 1.96 (dd, J = 13.7, 8.0 Hz, 1H), 1.47 
(ddd, J = 13.5, 8.0, 5.4 Hz, 1H), 1.12–0.94 (m, 21H); 13C NMR (101 MHz, CDCl3) δ 
72.3, 71.7, 58.7, 58.6, 39.1, 18.0, 12.1; m/z (ESI+) found [M+H]+ 273.1883, C14H29O3Si 




 (1R,2S,3R,4R)-2-Azido-4-((triisopropylsilyl)oxy)cyclopentane-1,3-diol (1.30.3). To a 
solution of (1R,2R,4R,5R)-4-((triisopropylsilyl)oxy)-6-oxabicyclo[3.1.0]hexan-2-ol (150 
mg, 0.55 mmol) in DMF (10 mL), tetrabutylammonium chloride (153 mg, 0.55 mmol) 
and sodium azide (358 mg, 5.5 mmol) were added. The reaction mixture was heated at 80 
ºC for 24 h. The solvent was removed under reduced pressure and the residue was diluted 
with water. The reaction mixture was extracted with ethyl acetate and was dried 
(Na2SO4). Evaporation of the solvent followed by column chromatography (silica gel, 
20% EtOAC/Hexane) provided the desired product as colorless oil. Rf = 0.30 (20% 
EtOAc/hexanes); IR (neat) 3320, 2102 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.24–4.12 
(m, 1H), 3.84 (dt, J = 7.8, 4.9 Hz, 1H), 3.53 (t, J = 7.4 Hz, 1H), 2.28 (d, J = 4.6 Hz, 1H), 
2.10 (m, 1H), 2.07–2.00 (m, 2H), 1.66 (m, 1H), 1.13–1.00 (m, 21H); 13C NMR (101 
MHz, CDCl3) δ 82.5, 75.1, 72.7, 72.2, 40.2, 17.9, 12.1; m/z (ESI+) found [M+H]+ 




 Stereo- and regiochemistry of the compound 1.30.3 was confirmed by 2D HNMR 
analysis of the corresponding diacetate 1.30.4, which was made by treating 1.30.3 with 
acetic anhydride and pyridine. IR (neat) 2104, 1747 cm-1; 1H NMR (400 MHz, CDCl3) δ 
5.09 (dd, J = 13.2, 6.1 Hz, 1H), 4.96 (t, J = 5.1 Hz, 1H), 4.34 (dd, J = 11.3, 5.7 Hz, 1H), 
3.71 (t, J = 5.5 Hz, 1H), 2.33 – 2.18 (m, 1H), 2.09 (s, 3H), 2.07 (s, 3H), 2.03–1.89 (m, 
1H), 1.16–0.90 (m, 21H); 13C NMR (101 MHz, CDCl3) δ 170.2, 170.0, 82.4, 75.8, 73.6, 
68.8, 38.0, 21.0, 20.9, 17.82, 17.78, 12.0. Both H1 and H3 show COSY correlation with 
H2 that confirms the regiochemistry of azide. Further existence of 1D NOE correlation of 
H1 with H3 and H2 with H4 confirms the stereochemistry of the compound 1.30.4, hence 











(1.31.1). To a solution of cyclopentenol 1.26.1 (300 mg, 1.17 mmol), phthalimide (344 
mg, 2.34 mmol) and triphenylphosphine (614 mg, 2.34 mmol)  in benzene (10 mL) 



















mixture stirred at rt for 24 h. The reaction mixture was quenched with water (10 mL) and 
was extracted with diethylether (3 × 30 mL). The combined organic layers were washed 
with brine, dried (Na2SO4), filtered, and concentrated. Column chromatography of the 
crude provided the desired product as viscous oil (319 mg, 68%). Rf = 0.74 (20% 
EtOAc/hexanes); IR (neat) 1698 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.85–7.74 (m, 2H), 
7.74–7.62 (m, 2H), 6.01 (ddd, J = 5.6, 2.5, 1.8 Hz, 1H), 5.86 (dt, J = 5.7, 1.7 Hz, 1H), 
5.10 (tq, J = 8.4, 2.0 Hz 1H), 4.91 (tq, J = 6.9, 1.7 Hz, 1H), 2.75 (dt, J = 12.3, 7.4 Hz, 
1H), 2.20–2.05 (ddd, J = 12.4, 8.4, 6.8 Hz, 1H), 1.16–0.95 (m, 21H); 13C NMR (101 
MHz, CDCl3) δ 168.1, 137.1, 134.0, 132.0, 130.8, 123.2, 75.6, 53.4, 40.4, 18.1, 12.21; 
m/z (ESI+) found [M+H]+ 386.2147, C22H32NO3Si requires 386.2151; [!]!!".! –97 (c 5.2, 





2-((1S,4R)-4-Hydroxycyclopent-2-en-1-yl)isoindoline-1,3-dione (1.31.2). To a solution 
of 2-((1S,4R)-4-((triisopropylsilyl)oxy)cyclopent-2-en-1-yl)isoindoline-1,3-dione (100 
mg, 0.25 mmol) in THF (5 mL), tetrabutylammonium fluoride (0.5 mL of 1M solution in 
THF, 0.5 mmol) was added dropwise and stirred at rt for 1 h. The reaction mixture was 
quenched with water (5 mL) and was extracted with ethyl acetate (3 × 30 mL). The 
combined organic layer was washed with brine, dried (Na2SO4), filtered, and 
concentrated. Column chromatography (silica gel, 30% EtOAc/Hexane) of the crude 





EtOAc/hexanes); IR (neat) 3315, 1697 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.86–7.79 
(m, 2H), 7.77–7.69 (m, 2H), 6.23 (dt, J = 5.6, 2.0 Hz 1H), 5.75 (dd, J = 5.5, 2.6 Hz, 1H), 
5.25 (ddd, J = 9.6, 4.4, 2.2 Hz, 1H), 4.76 (m, 1H), 4.15–4.01 (m, 1H), 2.84 (ddd, J = 15.4, 
9.6, 7.8 Hz, 1H), 1.99 (ddd, J = 15.4, 2.0, 1.5 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 
168.6, 138.6, 134.4, 131.9, 130.3, 123.5, 76.0, 53.1, 38.3; m/z (ESI+) found [M+H]+ 




(S)-2-(4-Oxocyclopent-2-en-1-yl)isoindoline-1,3-dione (1.31.3). To a solution of 2-
((1S,4R)-4-hydroxycyclopent-2-en-1-yl)isoindoline-1,3-dione (40 mg, 0.18 mmol) in 
dichloromethane (3 mL), pyridiniumchlorochromate (56 mg, 0.26 mmol) was added at 0 
ºC. The reaction mixture was stirred at RT for 1h and was diluted with Et2O (15 mL). The 
mixture was filtered through Celite. Evaporation of solvent followed by column 
chromatography (silica gel, 10% EtOAc/hexane) gave the desired product as colorless oil 
(36 mg, 91%). IR (neat) 1721, 1698 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.90–7.81 (m, 
2H), 7.80–7.70 (m, 2H), 7.52 (dd, J = 5.7, 2.4 Hz, 1H), 6.44 (dd, J = 5.7, 2.2 Hz, 1H), 
5.54 (ddt, J = 6.9, 3.3, 2.3 Hz, 1H), 2.80 (qd, J = 18.3, 5.2 Hz, 2H); 13C NMR (100.6 
MHz, CDCl3) δ 205.3, 167.7, 159.7, 136.3, 134.6, 131.8, 123.7, 49.8, 39.7; m/z (ESI+) 








9-((1S,4R)-4-((Triisopropylsilyl)oxy)cyclopent-2-en-1-yl)-9H-purin-6-amine (1.31.4 ). 
To a solution of (1R,4R)-4-((triisopropylsilyl)oxy)cyclopent-2-enol (100 mg, 0.39 mmol), 
adenine (106 mg, 0.78 mmol) and triphenylphosphine  (205 mg, 0.78 mmol)  in THF (10 
mL), diethyldiazocarboxylate (0.12 mL, 0.78 mmol) was added dropwise at rt and the 
reaction mixture stirred for 24 h. The reaction mixture was quenched with water (5 mL) 
and extracted with ethyl acetate (3 × 30 mL). The combined organic layer was washed 
with brine, dried (Na2SO4), filtered and concentrated.  Column chromatography (silica 
gel, 30% EtOAc/hexane) of the crude provided the desired product as viscous oil (103 
mg, 70%). Rf = 0.35 (30% EtOAc/hexanes); IR (neat) 3360 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 8.37 (s, 1H), 8.07 (s, 1H), 6.26 (dt, J = 5.6, 2.0 Hz, 1H), 6.23 (m, 2H), 6.00 (dd, 
J = 5.5, 2.2 Hz, 1H), 5.63 (m, 1H), 5.00 (dt, J = 6.8, 2.0 Hz, 1H), 2.96 (ddd, J = 14.9, 8.2, 
6.9 Hz, 1H), 1.88 (dt, J = 14.4, 3.1 Hz, 1H), 1.20–0.99 (m, 21H); 13C NMR (101 MHz, 
CDCl3) δ 155.8, 153.0, 149.7, 139.8, 139.3, 131.3, 119.6, 75.6, 56.7, 42.8, 18.1, 12.1; m/z 
(ESI+) found [M+H]+ 374.2370, C19H32N5OSi requires 374.2376; [!]!!".! –53 (c 0.6, 











(2R,4R)-1,5-Dichloro-4-((triisopropylsilyl)oxy)pentan-2-ol (2.14.1). To a solution of 
dichloro diol 1.21.5 (1.00 g, 5.76 mmol) in THF (60 mL) at  –78 ºC, n-BuLi (2.5 mL, 
5.76 mmol, 2.5 M in hexanes) was added dropwise. The reaction mixture was stirred at –
78 ºC for 30 min. Triisopropylsilyl chloride (1.11 g, 5.76 mmol) was added via syringe 
and the reaction mixture was brought to –40 ºC over 2 h. The reaction was allowed to stir 
at –40 ºC for 4 h and the progress of the reaction was monitored by TLC. The reaction 
was quenched with saturated aq NH4Cl and was extracted with diethyl ether. The 
combined organic layers were dried (Na2SO4), filtered and concentrated. The crude 
reaction mixture was purified by column chromatography to obtain the product as 
colorless oil in 94% yield (1.85 g). Rf = 0.35 (10% EtOAc/hexanes); IR (neat) 3360 cm-1; 
1H NMR (400 MHz, CDCl3) δ 4.34–4.28 (m, 1H), 4.16–4.05 (m, 1H), 3.59 (dd, J = 10.9, 
4.3 Hz, 1H), 3.57–3.51 (m, 2H), 3.49 (dd, J = 11.1, 6.2 Hz, 1H), 3.11 (s, 1H), 1.89–1.85 
(m, 2H), 1.14–1.02 (m, 21H); 13C NMR (101 MHz, CDCl3) δ 70.7, 68.1, 50.2, 47.2, 38.0, 
18.1, 18.07, 12.6; m/z (ESI+) found [M+H]+ 329.1470, C14H31Cl2O2Si requires 329.1470; 
[!]!!".!  +31.7 (c .86, DCM). (2S,4S)-2.14.1  [!]!!".!!–30.3 (c 1.0, DCM). 
 




 (((R)-1-Chloro-3-((R)-oxiran-2-yl)propan-2-yl)oxy)triisopropylsilane (2.14.2). To a 







mmol) in anhydrous Et2O (25 mL) dry KOH powder (0.56 g, 9.9 mmol) was added at 0 
ºC and the mixture was stirred at room temperature for 3 h. The reaction mixture was 
filtered through a bed of anhydrous MgSO4, and the MgSO4 was washed with diethyl 
ether. The filtrate was concentrated and was subjected to column chromatography to 
obtain the product as colorless oil in 97% yield (860 mg). Rf = 0.35 (30% 
EtOAc/hexanes); IR (neat) 2945, 2867, 2358,  cm-1; 1H NMR (400 MHz, CDCl3) δ 4.24 
(tt, J = 6.4, 4.6 Hz, 1H), 3.57 (dd, J = 4.5, 11.0 Hz, 1H), 3.53 (dd, J = 6.5, 11.0 Hz, 1H), 
3.09 (dddd, J = 6.6, 5.1, 3.9, 2.7 Hz, 1H), 2.82 (dd, J = 5.1, 4.0 Hz, 1H), 2.55 (dd, J = 5.1, 
2.7 Hz, 1H), 1.89 (ddd, J = 14.0, 6.2, 4.9 Hz, 1H), 1.86–1.79 (m, 1H), 1.12–1.03 (m, 
21H); 13C NMR (101 MHz, CDCl3) δ 70.8, 49.1, 48.4, 47.6, 38.2, 18.22, 18.20, 12.7; m/z 
(ESI+) found 293.1700 [M+H]+, C14H30ClO2Si requires 293.1704; [!]!!".! +25.1 (c 2.3 , 
DCM).  
 By following above procedure, (2S,4S)-2.14.1 (600 mg, 1.82 mmol) in anhydrous 
Et2O (20 mL) on treatment with dry KOH powder (306 mg, 5.5 mmol) provided (2S,4S)-







8-yl)oxy)silane (2.15.3). To a solution of tert-butyl(1,3-dithian-2-yl)dimethylsilane (46 
mg, 0.19 mmol) in THF (0.9 mL), n-BuLi (0.086 mL, 2.5 M in hexanes),  was added 




was transferred dropwise via syringe to a solution of epoxide (R,R)-2.14.2 (56 mg, 0.19 
mmol) in THF/HMPA (0.9 mL/0.1 mL) precooled to –40 ºC. The reaction mixture was 
stirred at –40 ºC for 30 min and then was allowed to rise to room temperature for 16 h. 
The reaction was diluted with water and was extracted with Et2O. The combined organic 
layer was washed with brine, dried (Na2SO4), filtered, and concentrated. The crude 
product was purified by column chromatography to obtain the product as colorless oil in 
69% yield (860 mg). Rf = 0.40 (5% EtOAc/hexanes); IR (neat) 2358, 2329 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 4.37 (tt, J = 7.6, 3.6 Hz, 1H), 4.25 (tt, J = 6.2, 3.4 Hz, 1H), 2.91 
(ddd, J = 14.4, 8.4, 3.5 Hz, 1H), 2.79 (ddd, J = 6.0, 3.8, 1.6 Hz, 2H), 2.74 (dt, J = 10.9, 
3.6 Hz, 1H), 2.44 (d, J = 13.4 Hz, 1H), 2.13 (dd, J = 13.9, 3.5 Hz, 1H), 2.01–1.74 (m, 
5H), 1.67 (ddd, J = 13.0, 7.9, 3.4 Hz, 1H), 1.07 (s, 21H), 0.89 (s, 9H), 0.06 (s, 3H), 0.04 
(s, 3H); 13C NMR (101 MHz, CDCl3) δ 67.0, 66.2, 48.6, 46.0, 45.6, 43.8, 26.8, 26.0, 
25.6, 18.3, 18.2, 12.5, -4.7, -4.8; m/z (ESI+) found [M+Na]+ 513.2685, C24H50O2S2SiNa 





(8R,10R)-1,5-Dithiaspiro[5.5]undecane-8,10-diol (2.15.4). To a solution of tert-
butyldimethyl(((8R,10R)-10-((triisopropylsilyl)oxy)-1,5-dithiaspiro[5.5]undecan-8-
yl)oxy)silane in THF (50 mg, 0.10 mmol), tetrabutylammonium fluoride (0.15 ml, 0.15 
mmol, 1M solution in THF) was added and the reaction mixture was stirred at room 




ethyl acetate. The combined organic layer was washed with brine, dried over Na2SO4, 
filtered and concentrated. The crude reaction mixture was purified by column 
chromatography to obtain the product as colorless oil in 91% yield (20 mg). Rf = 0.30 
(30% EtOAc/hexanes); IR (neat) 3360 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.29–4.22 (m, 
2H), 3.00–2.85 (m, 6H), 2.27 (dd, J = 14.0, 6.8 Hz, 2H), 2.18 (dd, J = 14.0, 4.1 Hz, 2H), 
2.02 (p, J = 5.7 Hz, 2H), 1.87 (t, J = 5.6 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 65.4, 
48.3, 43.9, 42.3, 26.5, 25.3; m/z (ESI+) found [M+H]+ 221.0672, C9H17O2S2 requires 







yl)oxy)silane (2.16.1). To a solution of (1,3-dithian-2-yl)trimethylsilane (36 mg, 0.18 
mmol) in THF (0.5 mL) n-BuLi (0.092 mL, 0.21 mmoL) was added dropwise at room 
temperature. The resulting yellow solution was stirred for 15 min and was transferred 
dropwise via syringe to a solution of epoxide (R,R)-2.14.2 (50 mg, 0.17 mmol) in 
THF/HMPA (1.7 mL/0.8 mL) precooled to –40 ºC. The resulting light yellow solution 
was stirred at –40 ºC for 1 h and was then brought to room temperature for 16 h. The 
reaction mixture was diluted with water and was extracted with diethyl ether. The 
combined organic layer was washed with brine, dried, filtered and concentrated. The 
crude product was purified by column chromatography to obtain the product as colorless 




NMR (400 MHz, CDCl3) δ 4.36 (td, J = 5.7, 2.9 Hz, 1H), 4.30 (dt, J = 8.0, 4.2 Hz, 1H), 
2.93 (ddd, J = 14.4, 8.5, 3.6 Hz, 1H), 2.87–2.77 (m, 2H), 2.77–2.71 (m, 1H), 2.47–2.38 
(m, 1H), 2.15 (dd, J = 14.1, 3.6 Hz, 1H), 2.05–1.87 (m, 3H), 1.81 (dt, J = 13.4, 8.4 Hz, 
2H), 1.67 (ddd, J = 12.5, 8.2, 3.4 Hz, 1H), 1.08 (s, 21H), 0.13 (s, 9H); 13C NMR (101 
MHz, CDCl3) δ 67.2, 65.9, 48.7, 46.0, 45.7, 43.8, 26.8, 26.7, 25.6, 18.33, 18.29, 12.5, 
0.2; m/z (ESI+) found [M+Na]+ 471.2219, C21H44O2S2Si2Na requires 471.2219; [!]!!".!  
+103.5 (c 2.1, DCM).  
 By following above procedure, 500 mg (1.71 mmol) of the (((S)-1-chloro-3-((S)-
oxiran-2-yl)propan-2-yl)oxy)triisopropylsilane was converted to (S,S)-(1.1 g, 2.4 mmol).  





 (1S,3S)-3-((Triisopropylsilyl)oxy)cyclohexanol (2.16.2). To a solution of 
triisopropyl(((8R,10R)-10-((trimethylsilyl)oxy)-1,5-dithiaspiro[5.5]undecan-8-
yl)oxy)silane (50 mg, 0.11 mmol) in ethanol (1 mL), Raney Nickel (0.3 mL suspension in 
water) was added in one portion and the reaction mixture was heated to reflux for 4 h. 
Reaction did not go to completion in 4h [Note: In some cases, an additional 5 mL 
suspension of Raney Nickel (washed with ethanol) was added and the reaction was 
refluxed for further 16 h.] The grey suspension was filtered through a plug of silica and 
the filtrate was concentrated. The crude reaction mixture was purified by column 
chromatography to obtain the product in 77% yield (20 mg, 0.085 mmol) as colorless oil. 
Rf = 0.32 (10% EtOAc/hexanes); IR (neat) 3378 cm-1; 1H NMR (400 MHz, CDCl3) δ 
HO OTIPS
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4.22 (tt, J = 5.8, 3.1 Hz, 1H), 4.07 (td, J = 8.9, 4.3 Hz, 1H), 2.00–1.66 (m, 3H), 1.66– 
1.42 (m, 7H), 1.41–1.19 (m, 2H), 1.13–0.92 (m, 18H); 13C NMR (101 MHz, CDCl3) δ 
68.2, 67.6, 43.5, 35.3, 34.3, 19.4, 18.6, 12.8; [!]!!".!  +39.5 (c 2.1, DCM); m/z (ESI+) 
found [M+Na]+ 295.2066, C15H32NaO2Si requires 295.2069. Chiral GC separation: Astec 
Chiraldex B-DM fused silica capillary column, 30m × 0.25 mm × 0.12 mm, temperature 
145 ºC, tR = 10.33 min, tS = 11.03 min, er 99>1.  
  Similarly, 1.02 g (2.28 mmol) of the triisopropyl (((8S,10S)-10-
((trimethylsilyl)oxy)-1,5-dithiaspiro[5.5]undecan-8-yl)oxy)silane in ethanol (20 mL) was 
treated with Raney-Nickel (5 mL of 50% aq suspension washed with ethanol) to provide 
(1R,3R)-3-((Triisopropylsilyl)oxy)cyclohexanol as colorless oil (430 mg, 1.35 mmol). 





(1S,3S)-Cyclohexane-1,3-diol (2.16.3). To a solution of (1S,3S)-3-
((triisopropylsilyl)oxy)cyclohexanol 2.16.2 (50 mg, 0.11 mmol) in THF (0.5 mL), 
tetrabutylammonium fluoride (0.15 ml, 0.15 mmol, 1M solution in THF) was added and 
the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was 
diluted with water and was extracted with ethyl acetate. The combined organic layer was 
washed with brine, dried (Na2SO4), filtered and concentrated. The crude reaction mixture 
was purified by column chromatography to obtain the product as colorless oil in 91% 
yield (20 mg). Rf = 0.2 (100% EtOAc); IR (neat) 3378 cm-1; 1H NMR (400 MHz, CDCl3) 
δ 4.15–4.06 (m, 2H), 1.83–1.55 (m, 8H), 1.52–1.35 (m, 2H); 13C NMR (101 MHz, 
HO OH
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CDCl3) δ67.1, 42.2, 33.9, 18.9; [!]!!".!  +3.7 (c 2.0, DCM); m/z (ESI+) found [M+Na]+ 
139.0734, C6H12NaO2 requires 139.0735.  
 By following above procedure, 410 mg (1.50 mmol) of the (1R,3R)-3-
((triisopropylsilyl)oxy)cyclohexanol was converted to (1R,3R)-cyclohexane-1,3-diol 






(3S,5S)-3-Hydroxy-5-((triisopropylsilyl)oxy)cyclohexanone (2.16.4). To a solution of 
triisopropyl(((8S,10S)-10-((trimethylsilyl)oxy)-1,5-dithiaspiro[5.5]undecan-8-
yl)oxy)silane (50 mg, 0.11 mmol) in acetonitrile (0.5 mL), HgCl2 (59 mg, 0.22 mmol) 
was added in one portion and the reaction mixture was stirred vigorously at room 
temperature for 16 h. The white suspension was filtered through a plug of silica and the 
filtrate was concentrated. The crude reaction mixture was purified by column 
chromatography to obtain the product in 76% yield (20 mg, 0.085 mmol) as a colorless 
oil. Rf = 0.33 (50% EtOAc/hexanes); IR (neat) 3380, 1719 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 4.51 (tt, J = 6.3, 3.4 Hz, 1H), 4.43 (t, J = 4.0 Hz, 1H), 2.72 (ddt, J = 14.2, 4.6, 
1.6 Hz, 1H), 2.56 (ddt, J = 14.3, 4.0, 1.2 Hz, 1H), 2.47 (ddt, J = 14.2, 5.6, 1.5 Hz, 1H), 
2.38 (ddd, J = 14.2, 8.2, 1.2 Hz, 1H), 2.18 (dddt, J = 13.1, 6.5, 3.8, 1.4 Hz, 1H), 2.00–
1.92 (m, 1H), 1.64 (s, 1H), 1.13–0.96 (m, 21H); 13C NMR (101 MHz, CDCl3) δ 207.6, 
67.1, 66.5, 50.4, 50.0, 41.7, 18.1, 12.3; m/z (ESI+) found [M+Na]+ 309.1859, 








(2R,4R)-1,5-Diiodo-4-((triisopropylsilyl)oxy)pentan-2-ol (2.18.1). A mixture of 
dichorodiol 2.14.1 (300 mg, 0.91 mmol) and NaI in acetone was allowed to reflux for 24 
h. The reaction mixture was concentrated and was subjected to  column chromatography 
to obtain the diiodo product as colorless oil in 94% yield (439 mg). Rf = 0.35 (10% 
EtOAc/hexanes); IR (neat) 3360 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.29 (ddt, J = 8.0, 
5.7, 4.1 Hz, 1H), 3.93–3.83 (m, 1H), 3.60 (dd, J = 11.0, 4.3 Hz, 1H), 3.54 (dd, J = 11.0, 
8.1 Hz, 1H), 3.31 (dd, J = 10.1, 4.5 Hz, 1H), 3.22 (dd, J = 10.1, 6.1 Hz, 1H), 3.20–3.16 
(m, 1H), 1.99 (ddd, J = 14.4, 5.7, 2.4 Hz, 1H), 1.85 (ddd, J = 14.1, 10.2, 3.5 Hz, 1H), 
1.10–1.05 (m, 21H); 13C NMR (101 MHz, CDCl3) δ 71.0, 67.6, 46.8, 40.0, 18.2, 18.1, 
15.2, 12.5; m/z (ESI+) found [M+H]+ 513.0180, C14H31I2O2Si requires 513.0183; [!]!!".!  
–22.7 (c 1.2 , DCM).  
 By following above procedure, (2S,4S)-2.18.1 was obtained in 90% yield using  






 (3R,5R)-1-Benzyl-5-((triisopropylsilyl)oxy)piperidin-3-ol (2.18.2). 
To a solution of diiodo diol (2R,4R)-2.19.1 (50 mg, 0.097) in ethanol, benzylamine 
(0.013 mL, 0.12 mmol) was added and the resulting mixture was refluxed for 16 h at 100 







combined organic layer was washed with brine, dried (Na2SO4), filtered and 
concentrated. The crude reaction mixture was purified by column chromatography to 
obtain the product as colorless oil in 71% yield (25 mg, 0.69 mmol). Rf = 0.35 (30% 
EtOAc/hexanes); IR (neat) 3310 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.34–7.21 (m, 5H), 
4.09 (tt, J = 9.7, 4.7 Hz, 1H), 3.95 (s, 1H), 3.56 (d, J = 3.0 Hz, 2H), 2.95 (ddt, J = 10.8, 
3.8, 1.8 Hz, 1H), 2.76 (ddt, J = 11.4, 3.8, 1.8 Hz, 1H), 2.50 (d, J = 10.3 Hz, 1H), 2.19 (dd, 
J = 11.5, 1.9 Hz, 1H), 2.14 (td, J = 5.3, 4.4, 3.2 Hz, 1H), 1.93 (dd, J = 10.7, 9.4 Hz, 1H), 
1.38 (ddd, J = 13.2, 10.4, 2.9 Hz, 1H), 1.08–0.91 (m, 21H); 13C NMR (101 MHz, CDCl3) 
δ 138.0, 129.1, 128.4, 127.3, 66.3, 65.4, 62.4, 61.4, 59.0, 41.3, 18.2, 12.4; m/z (ESI+) 
found [M+H]+ 364.2676, C21H38NO2Si requires 364.2672. [!]!!".!  +18.3 (c 2.1, DCM).  
 Similarly, a mixture of (2S,4S)-2.18.1 (710 mg, 1.38 mmol) on treatment with 
benzyl amine (1.66 mmol, 0.18 mL) in ethanol (40 mL) provided (3S,5S)-1-benzyl-5-
((triisopropylsilyl)oxy)piperidin-3-ol as colorless oil in 80% yield (402 mg, 1.11 mmol); 





(3R,5R)-1-Benzylpiperidine-3,5-diol (2.18.3). To a solution of (3R,5R)-2.19.2 (300 mg, 
0.83 mmol) in THF 1M tetrabutylammonium fluoride (1.2 mL, 1.2 mmol) was added and 
the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was 
diluted with water and was extracted with ethyl acetate. The combined organic layer was 




was purified by column chromatography to obtain the product as light brown oil (161 mg, 
0.78 mmol). Rf = 0.2 (5% MeOH/DCM); IR (neat) 3360 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.36–7.23 (m, 5H), 4.06–3.98 (m, 2H), 3.64–3.54 (m, 2H), 2.80–2.48 (m, 2H), 
2.45–2.27 (m, 2H), 2.13 (s, 2H), 1.82–1.71 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 
137.5, 129.3, 128.6, 127.6, 65.3, 62.4, 59.8, 40.4; m/z (ESI+) found [M+H]+ 208.1337, 
C12H18NO2 requires 208.1338; [!]!!".!  +16.1 (c 2.0, DCM). HPLC (Chiralpak IC column 
n-hexane/i-PrOH = 90/10, flow rate = 1.0 mL/min, tR,R = 22.96 min, tS,S = 24.67, er 
>99:1).  
Similarily, a solution of (3S,5S)-2.18.2 (395 mg, 1.08 mmol) in THF, on treatment 
with tetrabutylammonium fluoride (1.8 mL, 1M in THF) provided (3R,5R)-1-
benzylpiperidine-3,5-diol as colorless oil in 92% yield (220 mg, 1.0 mmol); [!]!!".! –17.0 





(3R,5R)-5-((Triisopropylsilyl)oxy)tetrahydro-2H-thiopyran-3-ol (2.20.1). To a 
solution of diiodo diol (2R,4R)-2.18.1 (50 mg, 0.15 mmol) in ethanol (1 mL), aqueous 
sodium sulfide (120 mg, 1.5 mmol) was added and the resulting mixture was refluxed for 
16 h at 100 ºC. The solvent was evaporated and the reaction mixture was extracted with 
ethyl acetate. The reaction mixture was diluted with water and was extracted with ethyl 
acetate. The combined organic layer was washed with brine, dried (Na2SO4), filtered and 
concentrated. The crude reaction mixture was purified by column chromatography to 




EtOAc/hexanes); IR (neat) 3421 cm-1; 1H NMR (400 MHz, CDCl3) δ 4.52 (m, 1H), 4.03 
(m, 1H), 3.82–3.67 (m, 2H), 2.90–2.77 (m, 1H), 2.77–2.63 (m, 1H), 2.26 (ddd, J = 13.4, 
7.4, 6.3 Hz, 1H), 1.82 (ddd, J = 13.0, 5.7, 3.6 Hz, 1H), 1.25 (s, 1H), 1.08–1.01 (m, 21H); 
13C NMR (101 MHz, CDCl3) δ 78.8, 76.0, 73.0, 41.1, 37.9, 18.2, 12.2; m/z (ESI+) found 
[M+H]+ 291.1814, C14H31O2SSi requires 291.1814; [!]!!".!  +17.6 (c 0.85, DCM). Chiral 
GC separation: Astec Chiraldex B-DM fused silica capillary column, 30m × 0.25 mm × 
0.12 mm, temperature 160 ºC, tR,R = 13.39 min, tS,S = 15.40 min, erR,R 97:3.  
  In an identical manner as described above, a solution of (2S,4S)-2.18.1 (1.23 g, 
2.41 mmol) in ethanol (40 mL), aqueous sodium sulfide (1.88 g, 24.1 mmol) on refluxing 
for 20 h at 100 ºC, followed by column chromatography provided (3S,5S)-5-
((triisopropylsilyl)oxy)tetrahydro-2H-thiopyran-3-ol  as light yellow oil in 87% yield 






 (3R,5R)-Tetrahydro-2H-thiopyran-3,5-diol (2.20.2). To a solution of (3R,5R)-2.20.1 
(312 mg, 1.21 mmol) in THF, tetrabutylammonium fluoride (1.8 mL, 1M in THF) was 
added and the reaction mixture was stirred at room temperature for 2 h. The reaction 
mixture was diluted with water and was extracted with ethyl acetate. The combined 
organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated. The 
crude reaction mixture was purified by column chromatography to obtain the product as 
colorless viscous mass in 92% yield (149 mg, 1.1 mmol). Rf = 0.25 (100% EtOAc); IR 




4.02 (m, 2H), 2.65 (ddd, J = 13.3, 3.1, 1.0 Hz, 2H), 2.44 (ddd, J = 13.3, 7.4, 1.1 Hz, 2H), 
2.23 (s, 2H), 1.73 (t, J = 5.5 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 65.6, 41.6, 35.3; 
m/z (ESI+) found [M+Na]+ 157.0297, C5H10NaO2S requires 157.0299; [!]!!".!  +6.3 (c 
2.1, EtOH).  
 Similarly, a solution of (3S,5S)-5-((triisopropylsilyl)oxy)tetrahydro-2H-thiopyran-
3-ol 2.20.1 (618 mg, 1.21 mmol) in THF, on treatment with tetrabutylammonium fluoride 
(1.8 mL, 1M in THF) provided (3S,5S)-tetrahydro-2H-thiopyran-3,5-diol as colorless 






 (1R,4S)-4-((triisopropylsilyl)oxy)cyclopent-2-enol (1.26.1). To a solution of (1S,4S)-4-
((triisopropylsilyl)oxy)cyclopent-2-enol (3.41 g, 13.2 mmol) in THF (100 mL), triphenyl 
phosphine (13.8 g, 52.8 mmol) and 4-nitrophenyl benzoic acid (8.8 g, 52.8) were added. 
Then diethylazodicarboxylate (8.3 mL, 52.8 mmol) was added dropwise and the reaction 
mixture was stirred at room temperature for overnight. The reaction mixture was 
quenched with ammonium chloride and was extracted with diethyl ether. The combined 
organic layer was washed with brine, dried (Na2SO4), filtered and concentrated. The 
residue was dissolved in methanol and sodium methoxide (20 mol%, 58 mg) was added 
and the reaction mixture was stirred at room temperature for 4 h. The reaction mixture 
was filtered through a plug of anhydrous magnesium sulfate and was concentrated. The 
product was obtained by column chromatography in 72% yield (2.4 g) as colorless oil. Rf 




5.88 (m, 2H), 4.73 (ddt, J = 6.9, 4.4, 1.3 Hz, 1H), 4.57 (ddt, J = 7.2, 4.6, 1.4 Hz, 1H), 
2.70 (dt, J = 13.9, 7.0 Hz, 1H), 2.15 (s, 1H), 1.56 (dt, J = 13.7, 4.5 Hz, 1H), 1.24–0.87 
(m, 21H); 13C NMR (101 MHz, CDCl3) δ 137.2, 135.7, 75.3, 75.2, 45.1, 18.1, 18.09, 
12.2; m/z (ESI+) found [M+H]+ 257.1934, C14H29O2Si requires 257.1937; [!]!!".!  –19.4 
(c 2.0, DCM). Ent-1.26.1 (2.43 g) was prepared starting from (1R,4R)-4-






4-Nitrophenyl ((1R,4R)-4-((triisopropylsilyl)oxy)cyclopent-2-en-1-yl) carbonate 
(R,R-3.5.1). To a solution of (1R,4R)-4-((triisopropylsilyl)oxy)cyclopent-2-enol (3.5 g, 
13.6 mmol) in THF (136 mL), at -78 ºC, n-BuLi (5.4 mL, 2.5 M in hexanes) was added 
dropwise. The solution was stirred for 30 minutes at –78 ºC and a solution of 4-
nitrophenyl chloroformate (5.48 g, 27.2 mmol, in 20 mL THF) was added to it quickly. 
The reaction mixture was stirred at –78 ºC for 1 h and was quenched with saturated 
ammonium chloride while reaction still at – 78 ºC.  The reaction was extracted with 
diethyl ether. The combined organic layer was washed with brine, dried (Na2SO4), 
filtered and concentrated. The crude reaction mixture was purified by column 
chromatography to obtain the product as colorless oil in 77% yield (4.4 g). Rf = 0.45 
(10% EtOAc/hexanes); IR (neat) 1770 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.28 (d, J = 
9.2 Hz, 2H), 7.39 (d, J = 9.2 Hz, 2H), 6.14 (dt, J = 5.6, 1.6 Hz, 1H), 5.99 (ddd, J = 5.6, 
1.9, 1.3 Hz, 1H), 5.51 (ddt, J = 7.3, 5.0, 1.0 Hz, 1H), 4.84 (ddt, J = 6.9, 4.8, 1.0 Hz, 1H), 






NMR (101 MHz, CDCl3) δ 155.7, 152.3, 145.5, 143.4, 129.7, 125.4, 121.9, 84.6, 76.2, 
41.6, 18.1, 12.2; m/z (ESI+) found [M+H]+ 422.1999, C21H32NO6Si requires 422.1999; 
[!]!!".! +23.5 (c 0.95, DCM). 4-Nitrophenyl ((1S,4S)-4-((triisopropylsilyl)oxy)cyclopent-
2-en-1-yl) carbonate S,S-3.5.2 was obtained in similar manner from (1S,4S)-4-






4-Nitrophenyl ((1S,4R)-4-((triisopropylsilyl)oxy)cyclopent-2-en-1-yl) carbonate (S,R-
3.5.1). Starting with 3.5 g (13.6 mmol) of (1S,4R)-4-((triisopropylsilyl)oxy)cyclopent-2-
enol, the carbonate product was obtained in 77% yield (4.4 g, 10.4 mmol) as a colorless 
oil. Rf = 0.42 (10% EtOAc/hexanes); IR (neat) 1769 cm-1; δ 1H NMR (400 MHz, CDCl3) 
δ 8.25 (d, J = 9.2 Hz, 2H), 7.36 (d, J = 9.2 Hz, 2H), 6.21 (dd, J = 5.8, 1.9 Hz, 1H), 6.04 
(ddd, J = 5.6, 2.4, 1.4 Hz, 1H), 5.82 (dd, J = 7.0, 2.0 Hz, 1H), 5.20 (ddd, J = 6.3, 4.1, 1.8 
Hz, 1H), 2.40 (ddd, J = 14.7, 6.6, 1.9 Hz, 1H), 2.16 (ddd, J = 14.7, 6.9, 4.2 Hz, 1H), 
1.18–0.98 (m, 21H); 13C NMR (101 MHz, CDCl3) δ 152.3, 145.5, 140.9, 129.7, 125.4, 
122.0, 82.3, 74.8, 41.2, 18.11, 18.09, 17.8, 12.2; m/z (ESI+) found [M+H]+ 422.1992 , 
C21H31NO6Si requires 422.1999; [!]!!".!  –27.1 (c 0.15, DCM).  
 Starting with 1.7 g (6.6 mmol) of (1R,4S)-4-((triisopropylsilyl)oxy)cyclopent-2-
enol, carbonate product S,R-3.5.1 was obtained in 79% yield (2.2 g, 5.2 mmol) as a 












A solution of the carbonate 3.5.1 (1 eq, 1.8 mmol) in THF (10 mL) was added to a 20 mL 
microwave vial placed on a heating block fitted on a magnetic stirrer. N,N’-dimethyl 
aminopyridine (10 mol%), Hunig’s base (2 eq) and amino acid hydrochloride (1.2 eq) 
were added and the vial was sealed with an aluminum cap. The reaction mixture was 
heated at 80 ºC for 18 h. The solvent was evaporated and the crude product was purified 
by column chromatography (silica gel, ethyl acetate/hexane as eluent) to obtain the 
product 3.7.1 in 79–84% yield. All of the sixteen isomers of 3.7.1 were prepared on 600–
700 mg scale. Each of the isomers were individually purified using silica-gel column 
chromatography, and were characterized by nmr and mass analysis. The characterization 





























R1 = 3-indolyl ylmethyl,        
       methyl, proline      












EtOAc/hexanes); IR (neat) 1747, 1715 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.21 (s, 1H), 
7.61 (d, J = 7.9 Hz, 1H), 7.40–7.29 (m, 1H), 7.19 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.12 
(ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 7.01 (d, J = 2.3 Hz, 1H), 6.04 (dd, J = 5.8, 1.8 Hz, 1H), 
5.93 (dt, J = 5.9, 1.7 Hz, 1H), 5.74 (dt, J = 7.2, 2.3 Hz, 1H), 5.18 (d, J = 8.1 Hz, 1H), 
5.13–5.06 (m, 1H), 4.59 (dt, J = 8.2, 5.8 Hz, 1H), 3.27 (qd, J = 14.8, 5.8 Hz, 2H), 2.16 
(ddd, J = 14.5, 5.4, 2.6 Hz, 1H), 2.11–2.02 (m, 1H), 1.38 (s, 9H), 1.06 (d, J = 4.3 Hz, 
21H); 13C NMR (101 MHz, CDCl3) δ 171.3, 155.9, 140.9, 136.2, 131.8, 128.0, 122.8, 
122.2, 119.6, 119.1, 111.2, 110.5, 82.1, 79.7, 76.4, 55.1, 41.7, 28.1, 18.1, 12.2; m/z 







 (S)-2-tert-Butyl 1-((1R,4R)-4-((triisopropylsilyl)oxy)cyclopent-2-en-1-yl) 
pyrrolidine-1,2-dicarboxylate (S,R,R-3.7.2). Yield 82%; Rf = 0.3 (30% 
EtOAc/hexanes); IR (neat) 1749, 1713 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.06–5.91 
(m, 4H), 5.83 (d, J = 8.4 Hz, 1H), 5.69 (m, 1H), 5.10 (ddd, J = 6.7, 4.1, 2.0 Hz, 1H), 4.39 
(dt, J = 9.0, 4.7 Hz, 1H), 2.85 (dd, J = 16.0, 5.1 Hz, 1H), 2.70 (dd, J = 16.0, 4.4 Hz, 1H), 
2.18 (ddd, J = 14.4, 6.7, 2.3 Hz, 1H), 2.05 (ddd, J = 14.4, 7.0, 4.0 Hz, 1H), 1.42 (s, 10H), 
1.08–0.99 (m, 21H); 13C NMR (101 MHz, CDC3) δ 172.7, 170.2, 156.4, 141.0, 131.7, 
126.2, 115.8, 82.5, 79.9, 76.4, 51.3, 41.6, 37.6, 28.0, 18.0, 12.2; m/z (ESI+) found 











1-yl)oxy)carbonyl)amino)butanoate (S,R,R-3.7.3).  Yield 79%; Rf = 0.32 (70% 
EtOAc/hexanes); IR (neat) 1745, 1715 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.01–5.95 
(m, 1H), 5.95–5.87 (m, 1H), 5.74–5.65 (m, 1H), 5.11–4.98 (m, 1H), 4.17–4.04 (m, 1H), 
3.58–3.27 (m, 2H), 2.21–1.97 (m, 3H), 1.95–1.73 (m, 2H), 1.43–1.35 (m, 9H), 1.06–0.95 
(m, 21H); 13C NMR (101 MHz, CDCl3) δ 172.5, 170.3, 156.4, 141.1, 140.2, 82.5, 79.9, 
76.3, 51.3, 41.6, 29.9, 28.0, 18.1, 12.1; m/z (ESI+) found [M+H]+ 471.2990, 







yl)oxy)carbonyl)amino)propanoate (S,R,R-3.7.4).  Yield 83%; Rf = 0.40 (20% 
EtOAc/hexanes); IR (neat) 1747, 1711 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.02–5.99 
(m, 1H), 5.95–5.88 (m, 1H), 5.75–5.65 (m, 1H), 5.22 (m, 1H), 5.09 (qd, J = 3.8, 1.7 Hz, 
1H), 4.18–4.01 (m, 1H), 2.17 (ddd, J = 14.4, 6.7, 2.3 Hz, 1H), 2.05 (ddd, J = 14.5, 7.0, 
4.0 Hz, 1H), 1.42 (s, 9H), 1.32 (d, J = 7.2 Hz, 3H), 1.12–0.93 (m, 21H); 13C NMR (101 
MHz, CDCl3) δ 172.3, 155.7, 140.8, 131.8, 81.8, 79.6, 76.4, 50.1, 41.7, 28.0, 19.0, 18.0, 
12.2; m/z (ESI+) found [M+H]+ 428.2832, C22H42NO5Si requires 428.2832; [!]!!".! –69.7 

















en-1-yl)oxy)carbonyl)amino)propanoate (S,S,R-3.7.1). Yield 81%; Rf = 0.20 (20% 
EtOAc/hexanes); IR (neat) 1744, 1713 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.60–8.31 
(m, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.19 (ddd, J = 8.1, 7.0, 1.2 
Hz, 1H), 7.15–7.07 (m, 1H), 7.00 (d, J = 2.3 Hz, 1H), 6.08 (dd, J = 5.6, 1.9 Hz, 1H), 5.93 
(dt, J = 5.7, 1.8 Hz, 1H), 5.78–5.53 (m, 1H), 5.40–5.15 (m, 1H), 5.14–4.95 (m, 1H), 
4.70–4.30 (m, 1H), 3.28 (qd, J = 14.9, 5.8 Hz, 2H), 2.19 (ddd, J = 14.5, 6.7, 2.2 Hz, 1H), 
2.11–2.00 (m, 1H), 1.42 (s, 9H), 1.06 (d, J = 3.9 Hz, 21H); 13C NMR (101 MHz, CDCl3) 
δ 171.5, 162.8, 156.4, 140.9, 139.1, 136.2, 131.2, 127.6, 123.0, 122.3, 119.7, 111.3, 
109.8, 82.7, 78.0, 74.9, 55.2, 41.5, 28.0, 17.98, 17.95, 12.1; m/z (ESI+) found [M+H]+ 






 (S)-2-tert-Butyl 1-((1S,4R)-4-((triisopropylsilyl)oxy)cyclopent-2-en-1-yl) pyrrolidine-
1,2-dicarboxylate (S,S,R-3.7.2).  Yield 79%; Rf = 0.35 (70% EtOAc/hexanes); IR (neat) 
1749, 1715 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.94–5.72 (m, 2H), 5.42–5.29 (m, 1H), 
4.70 (m, 1H), 4.12–4.08 (m, 1H), 3.57–3.25 (m, 2H), 2.87–2.71 (m, 1H), 2.22–1.71 (m, 















172.0, 154.7, 138.3, 131.8, 81.1, 77.5, 74.9, 46.8, 42.0, 30.9, 28.0, 24.2, 23.5, 17.99, 
17.98, 12.2; m/z (ESI+) found [M+H]+ 454.2989, C24H44NO5Si requires 454.2989; [!]!!".! 







1-yl)oxy)carbonyl)amino)butanoate (S,S,R-3.7.3). Yield 80%; Rf = 0.40 (20% 
EtOAc/hexanes); IR (neat) 1745, 1700, cm-1; 1H NMR (400 MHz, CDCl3) δ 6.17–5.82 
(m, 4H), 5.38 (t, J = 6.5 Hz, 1H), 4.75 (dtd, J = 7.2, 2.8, 1.3 Hz, 1H), 4.56–3.89 (m, 1H), 
2.98–2.53 (m, 3H), 1.63 (dt, J = 13.7, 5.1 Hz, 1H), 1.42 (s, 9H), 1.35–1.12 (m, 1H), 1.11–
0.91 (m, 21H); 13C NMR (101 MHz, CDCl3) δ 172.7, 163.3, 156.3, 139.0, 126.2, 115.8, 
82.5, 77.7, 74.9, 51.3, 41.8, 37.6, 28.0, 18.03, 18.01, 12.2; m/z (ESI+) found [M+H]+ 







yl)oxy)carbonyl)amino)propanoate (S,S,R-3.7.4). Yield 82%; Rf = 0.42 (20% 
EtOAc/hexanes); IR (neat) 1747, 1710 cm-1; 1H NMR (400 MHz, CDCl3) δ 5.94 (dt, J = 
5.6, 1.6 Hz, 1H), 5.92–5.78 (m, 1H), 5.54–5.01 (m, 2H), 4.87–4.60 (m, 1H), 4.27–3.92 













(d, J = 7.1 Hz, 3H), 1.03–0.99 (m, 21H); 13C NMR (101 MHz, CDCl3) δ 172.2, 155.6, 
138.8, 131.5, 81.8, 77.4, 74.9, 50.2, 41.7, 28.0, 18.0, 12.1; m/z (ESI+) found [M+H]+ 






en-1-yl)oxy)carbonyl)amino)propanoate (S,S,S-3.7.1).  Yield 80%; Rf = 0.22 (20% 
EtOAc/hexanes); IR (neat) 1744, 1712 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.60–8.31 
(m, 1H), 7.59 (d, J = 7.9 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.19 (ddd, J = 8.1, 7.0, 1.2 
Hz, 1H), 7.15–7.07 (m, 1H), 7.00 (d, J = 2.3 Hz, 1H), 6.08 (dd, J = 5.6, 1.9 Hz, 1H), 5.93 
(dt, J = 5.7, 1.8 Hz, 1H), 5.78–5.53 (m, 1H), 5.40–5.15 (m, 1H), 5.14–4.95 (m, 1H), 
4.70–4.30 (m, 1H), 3.28 (qd, J = 14.9, 5.8 Hz, 2H), 2.19 (ddd, J = 14.5, 6.7, 2.2 Hz, 1H), 
2.11–2.00 (m, 1H), 1.42 (s, 9H), 1.06 (d, J = 3.9 Hz, 21H); 13C NMR (101 MHz, CDCl3) 
δ 171.5, 156.4, 136.2, 131.3, 127.7, 126.2, 122.9, 122.2, 119.6, 118.8, 115.7, 111.3, 82.5, 
80.2, 76.3, 55.2, 41.5, 28.0, 18.0, 12.1; m/z (ESI+) found [M+H]+ 543.3250, 















 (S)-2-tert-Butyl 1-((1S,4R)-4-((triisopropylsilyl)oxy)cyclopent-2-en-1-yl) pyrrolidine-
1,2-dicarboxylate (S,S,S-3.7.2). Yield 83%; Rf = 0.42 (20% EtOAc/hexanes); IR (neat) 
1745, 1715 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.17–5.82 (m, 4H), 5.38 (t, J = 6.5 Hz, 
1H), 4.75 (dtd, J = 7.2, 2.8, 1.3 Hz, 1H), 4.56–3.89 (m, 1H), 2.98–2.53 (m, 3H), 1.63 (dt, 
J = 13.7, 5.1 Hz, 1H), 1.42 (s, 9H), 1.35–1.12 (m, 1H), 1.11–0.91 (m, 22H); 13C NMR 
(101 MHz, CDCl3) δ 172.7, 170.3, 163.3, 156.3, 139.0, 131.4, 126.2, 115.8, 82.5, 77.7, 
74.9, 51.3, 41.8, 37.6, 28.0, 18.0 (d, J = 1.8 Hz), 12.2; m/z (ESI+) found [M+H]+ 







yl)oxy)carbonyl)amino)butanoate (S,S,S-3.7.3). Yield 77%; Rf = 0.34 (70% 
EtOAc/hexanes); IR (neat) 1746, 1699 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.03–5.60 
(m, 2H), 5.39 (m, 1H), 4.73 (dtd, J = 7.1, 5.1, 2.4 Hz, 1H), 4.11 (m, 1H), 3.46–3.80 (m, 
2H), 2.94–2.67 (m, 1H), 2.25–1.74 (m, 3H), 1.62 (m, 1H), 1.40 (m, 9H), 1.02 (m, 21H); 
13C NMR (101 MHz, CDCl3) δ 172.0, 154.7, 154.4, 138.4, 138.3, 132.2, 131.8, 81.1, 





















yl)oxy)carbonyl)amino)propanoate (S,S,S-3.7.4). Yield 80%; Rf = 0.45 (20% 
EtOAc/hexanes); IR (neat) 1747, 1717 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.04 (dd, J = 
5.7, 1.8 Hz, 1H), 5.94 (ddd, J = 5.6, 2.4, 1.4 Hz, 1H), 5.79–5.58 (m, 1H), 5.25–4.88 (m, 
2H), 4.35–3.83 (m, 1H), 2.19 (ddd, J = 14.5, 6.7, 2.2 Hz, 1H), 2.05 (ddd, J = 14.4, 7.0, 
4.1 Hz, 1H), 1.44 (s, 9H), 1.33 (d, J = 7.2 Hz, 3H), 1.12–0.96 (m, 21H); 13C NMR (101 
MHz, CDCl3) δ 172.4, 155.7, 141.0, 131.7, 81.9, 79.7, 76.4, 50.2, 41.7, 28.1, 19.0, 
18.1.05, 18.04, 12.2; m/z (ESI+) found [M+H]+ 428.2829, C22H42NO5Si requires 







en-1-yl)oxy)carbonyl)amino)propanoate (S,R,S-3.7.1). Yield 79%; Rf = 0.22 (20% 















7.61 (d, J = 7.8 Hz, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.18 (t, J = 7.2 Hz, 1H), 7.12 (t, J = 7.4 
Hz, 1H), 6.98 (d, J = 2.4 Hz, 1H), 5.99 (d, J = 5.8 Hz, 1H), 5.86 (d, J = 5.6 Hz, 1H), 
5.52–5.15 (m, 2H), 4.78 (t, J = 6.3 Hz, 1H), 4.60 (dt, J = 8.2, 5.8 Hz, 1H), 3.27 (m, 2H), 
2.87 (dt, J = 14.1, 7.3 Hz, 1H), 1.65 (dt, J = 13.6, 5.3 Hz, 1H), 1.39 (s, 9H), 1.09 (d, J = 
4.5 Hz, 21H); 13C NMR (101 MHz, CDCl3) δ 171.2, 155.8, 138.8, 136.2, 131.6, 127.9, 
122.9, 122.1, 119.6, 119.0, 111.2, 110.3, 82.0, 77.4, 75.0, 55.1, 53.5, 41.9, 28.0, 18.06, 
18.05, 12.2; m/z (ESI+) found [M+H]+ 543.3250, C30H47N2O5Si requires 543.3254; 






 (S)-2-tert-Butyl 1-((1R,4S)-4-((triisopropylsilyl)oxy)cyclopent-2-en-1-yl) pyrrolidine-
1,2-dicarboxylate (S,R,S-3.7.2). Yield 80%; Rf = 0.35 (20% EtOAc/hexanes); IR (neat) 
1749, 1715 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.03–5.79 (m, 2H), 5.56–5.31 (m, 1H), 
4.90–4.55 (m, 1H), 4.18 (m, 1H), 3.69–3.22 (m, 2H), 2.84 (m, 1H), 2.16 (dd, J = 6.5, 2.8 
Hz, 1H), 2.03–1.75 (m, 3H), 1.72–1.51 (m, 1H), 1.42 (m, 9H), 1.03 (m, 21H); 13C NMR 
(101 MHz, CDCl3) δ 172.1, 154.8, 138.5, 132.1, 81.2, 77.5, 75.0, 59.9, 46.5, 30.9, 28.1, 
24.3, 23.5, 18.06, 18.04, 12.1; m/z (ESI+) found [M+H]+ 454.2985, C24H44NO5Si requires 












1-yl)oxy)carbonyl)amino)butanoate (S,R,S-3.7.3).  Yield 78%; Rf = 0.35 (30% 
EtOAc/hexanes); IR (neat) 1744, 1704 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.21 (s, 2H), 
6.08–5.88 (m, 2H), 5.83 (dt, J = 5.6, 1.6 Hz, 1H), 5.36 (t, J = 6.4 Hz, 1H), 4.85–4.58 (m, 
1H), 4.38 (dt, J = 9.6, 5.0 Hz, 1H), 2.90–2.70 (m, 2H), 2.65 (dd, J = 16.3, 4.2 Hz, 1H), 
1.59 (dt, J = 13.6, 5.3 Hz, 1H), 1.39 (s, 9H), 1.00 (d, J = 4.6 Hz, 21H); 13C NMR (101 
MHz, CDCl3) δ 172.7, 170.3, 156.2, 138.8, 131.5, 82.2, 77.5, 74.9, 51.3, 41.7, 37.5, 27.9, 
17.92, 17.90 12.1; m/z (ESI+) found [M+H]+ 471.2889, C23H43N2O6Si requires 471.2890; 







yl)oxy)carbonyl)amino)propanoate (S,R,S-3.7.4). Yield 82%; Rf = 0.42 (20% 
EtOAc/hexanes); IR (neat) 1749, 1712 cm-1; 1H NMR (400 MHz, CDCl3) δ 6.01–5.92 
(m, 1H), 5.92–5.72 (m, 1H), 5.62–5.02 (m, 2H), 4.90–4.62 (m, 1H), 4.39–3.87 (m, 1H), 
2.84 (dt, J = 14.1, 7.3 Hz, 1H), 1.72–1.52 (m, 1H), 1.45 (s, 9H), 1.35 (d, J = 7.1 Hz, 3H), 
1.12–0.96 (m, 21H); 13C NMR (101 MHz, CDCl3) δ 172.22, 155.5, 138.7, 131.6, 81.8, 
77.3, 74.9, 50.1, 41.9, 28.0, 18.9, 18.01, 17.99, 12.16; m/z (ESI+) found [M+H]+ 




















Step I. Each of the silyl monocarbamates 3.7.1–3.7.4 were treated with 
tetrabutylammonium fluoride (2 equiv) in THF for 2h. The reaction was quenched with 
water and extracted with ethyl acetate. The organic layer was dried (Na2SO4), filtered and 
concentrated to obtain the corresponding unprotected alcohol that was used as starting for 
the next without subsequent purification.  
 
Step II. To 2 dram vials placed on a 6x4-well heating block, 50 mg of the alcohol 
obtained in step I, amino acid isocyanate (3 eq) and 10% N,N’-DMAP were added. The 
block was heated to 100 ºC for 2 h. After cooling, 2 mL of dichloromethane was added to 
each vial. The contents were transferred to collection tubes, purged with nitrogen gas in a 
sample evaporator. The crude reaction mixtures (S,R,R,S)-3.9.7–(S,R,R,S)-3.9.30 on 














































range of 4–62 mg. A random subset of ten compounds from the crude library of the 72 
compound library [(S,S,R,S)-3.9.7–(S,S,R,S)-3.9.30, [(S,S,S,S)-3.9.7–(S,S,S,S)-3.9.30 and 
(S,R,S,S)-3.9.7–(S,R,S,S)-3.9.30] were purified by column chromatography to obtain the 
25–37 mg of the desired biscarbamate products (the spectral data are listed below). The 
rest of the crude library compounds were subjected to mass-directed purification and 
analysis.  
 






yl)propanoate (3.9.7). Yield 29%; Rf = 0.3 (30% EtOAc/hexanes); IR (neat) 1749, 1693 
cm-1; 1H NMR (400 MHz, CDCl3) δ 8.40 (s, 1H), 7.62 (d, J = 7.9 Hz, 1H), 7.50–6.82 (m, 
9H), 6.06 (s, 2H), 5.73 (d, J = 5.9 Hz, 2H), 5.22 (dd, J = 20.4, 8.3 Hz, 2H), 4.77–4.49 (m, 
2H), 3.37–3.18(m, 2H), 3.14–3.00 (m, 2H), 2.14 (t, J = 5.1 Hz, 2H), 1.43 (s, 9H), 1.41 (s, 
9H); 13C NMR (101 MHz, CDCl3) δ 171.2, 171.1, 170.7, 155.7, 136.2, 135.6, 129.6, 
128.5, 127.9, 127.1, 122.8, 122.2, 119.6, 118.9, 111.3, 110.4, 82.4, 82.1, 79.1, 78.9, 60.5, 
55.3, 53.5, 38.6, 37.9, 28.1, 21.1, 14.3; m/z (ESI+) found [M+H]+ 634.3130, C35H44N3O8 


















(3.9.9). Yield 44%; Rf = 0.2 (30% EtOAc/hexanes); IR (neat) 1749, 1703 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 8.32 (m, 1H), 7.62 (d, J = 7.8 Hz, 1H), 7.37 (d, J = 8.0 Hz, 1H), 
7.21 (ddd, J = 8.1, 7.0, 1.3 Hz, 1H), 7.14 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H), 7.04 (d, J = 2.3 
Hz, 1H), 6.22–5.92 (m, 2H), 5.84–5.51 (m, 2H), 5.15 (m, 2H), 4.72–4.20 (m, 1H), 3.39–
3.16 (m, 2H), 2.17 (m, 2H), 1.78–1.55 (m, 1H), 1.48 (s, 9H), 1.41 (s, 9H), 1.04–0.88 (m, 
9H); 13C NMR (101 MHz, CDCl3) δ 172.4, 171.2, 155.7, 136.2, 135.8, 135.6, 127.9, 
122.8, 122.3, 119.7, 119.0, 111.3, 110.5, 100.1, 82.1, 82.0, 79.0, 55.1, 42.2, 38.0, 29.8, 
28.1, 28.07, 25.0, 23.0, 22.1, 21.2; m/z (ESI+) found [M+H]+ 600.3285, C32H46N3O8 








(3.9.11). Yield 62%; Rf = 0.4 (30% EtOAc/hexanes); IR (neat) 1748, 1714, 1693 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 8.44 (s, 1H), 7.61 (d, J = 7.8 Hz, 1H), 7.36 (d, J = 8.0 Hz, 

















2.3 Hz, 1H), 6.07 (s, 2H), 5.87–5.48 (m, 2H), 5.43–5.17 (m, 2H), 4.74–4.20 (m, 2H), 
3.37–3.16 (m, 2H), 2.50–2.12 (m, 5H), 1.99–1.81 (m, 1H), 1.48 (s, 9H), 1.47 (s, 9H), 
1.40 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 172.2, 171.2, 155.9, 155.7, 136.2, 135.7, 
135.6, 127.9, 122.9, 122.2, 119.6, 118.9, 111.3, 110.7, 110.3, 82.4, 82.1, 80.8, 79.1, 78.9, 
55.1, 54.0, 37.8, 31.6, 28.2, 28.1, 28.0, 21.1, 14.3; m/z (ESI+) found [M+H]+ 672.3490, 








butoxy)phenyl)propanoate 3.9.8). Yield 67%; Rf = 0.3 (30% EtOAc/hexanes); IR (neat) 
1748, 1728, 1715, 1693 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.25 (m, 1H), 7.59 (d, J = 
7.9 Hz, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.22–7.14 (m, 1H), 7.15–7.09 (m, 1H), 7.09–6.98 
(m, 3H), 6.91 (d, J = 8.1 Hz, 2H), 6.05 (s, 2H), 5.87–5.47 (m, 2H), 5.25–4.87 (m, 2H), 
4.72–4.21 (m, 2H), 3.34–3.14 (m, 2H), 3.02 (d, J = 6.1 Hz, 2H), 2.23–2.07 (m, 2H), 1.38 
(s, 9H), 1.38 (s, 9H), 1.32 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 171.2, 170.7, 155.7, 
155.6, 154.5, 136.2, 135.7, 131.1, 130.1, 127.9, 124.2, 122.8, 122.3, 121.7, 119.7, 119.0, 
111.3, 110.5, 82.4, 82.2, 79.1, 78.9, 78.6, 55.3, 55.1, 38.1, 37.9, 29.0, 28.1, 21.2, 14.2; 
















(3.9.10). Yield 52%; Rf = 0.2 (30% EtOAc/hexanes); IR (neat) 1745, 1727, 1699 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 8.16 (m, 1H), 7.60 (d, J = 7.7 Hz, 1H), 7.35 (d, J = 8.1 Hz, 
1H), 7.19 (dd, J = 8.1, 1.2 Hz, 1H), 7.11 (dd, J = 8.0, 7.0, 1.1 Hz, 1H), 7.03 (m, 1H), 6.05 
(m, 2H), 5.56 - 5.37 (m, 2H), 5.37 - 4.99 (m, 2H), 4.73 – 4.08 (m, 2H), 3.41 – 3.05 (m, 
2H), 2.95 – 2.64 (m, 1H), 2.51 (m, 2H), 2.12 (m, 4H), 1.92 (m, 1H), 1.74 (dt, J = 14.9, 
3.6 Hz, 1H), 1.47 (s, 9H), 1.37 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 171.0, 170.6, 
155.5, 155.4, 136.1, 134.8, 134.6, 127.8, 122.6, 122.2, 119.5, 118.9, 111.1, 110.4, 82.4, 
82.0, 79.1, 78.9,  54.8, 53.7, 37.3, 32.4, 29.9, 28.0, 27.9, 15.5; 15.4; m/z (ESI+) found 








butoxy)phenyl)propanoate (3.9.12). Yield 56%; Rf = 0.4 (30% EtOAc/hexanes); IR 



















1H), 7.38 - 7.31 (m, 1H), 7.18 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.11 - 6.90 (m, 4H), 6.90 
(d, J = 8.5 Hz, 2H), 6.04 (s, 2H), 5.48 – 5.36 (m, 2H), 5.19 (dd, J = 27.1, 8.1 Hz, 2H), 
4.64 - 4.41 (m, 2H), 3.41 - 2.60 (m, 5H), 1.83 – 1.43 (m, 1H), 1.37 (s, 18H), 1.32 (s, 9H); 
13C NMR (101 MHz, CDCl3) δ 171.2, 170.8, 155.5, 155.3, 154.4, 136.2, 135.0, 134.7, 
131.0, 130.1, 127.9, 124.3, 122.8, 122.3, 119.6, 119.1, 111.2, 110.5, 82.4, 82.2, 78.5, 
77.5, 77.2, 76.8, 55.4, 54.9, 38.1, 37.5, 30.0, 28.1, 15.4; m/z (ESI+) found [M+H]+ 







yl)carbamoyl)oxy)cyclopent-2-en-1-yl) 2-tert-butyl pyrrolidine-1,2-dicarboxylate 
(3.9.19). Yield 62%; Rf = 0.3 (30% EtOAc/hexanes); IR (neat) 1748, 1714, 1693 cm-1; 1H 
NMR (400 MHz, CDCl3) 7.30 – 7.14 (m, 3H), 7.13 - 7.05 (m, 2H), 6.11 – 5.80 (m, 2H), 
5.58 – 5.30 (m, 2H), 5.16 - 4.82 (m, 1H), 4.55 – 4.22 (m, 1H), 4.21–4.02 (m, 1H), 3.58 – 
3.26 (m, 2H), 3.00 (m, 2H), 2.87 - 2.70 (m, 1H), 2.24 – 2.01 (m, 1H), 1.98 – 1.46 (m, 
4H), 1.38 (m, 9H), 1.33 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 172.0, 171.9, 170.7, 
155.4, 154.7, 154.6, 136.2, 135.0, 134.3, 129.6, 82.4, 81.2, 81.3, 60.7, 55.2, 46.9, 46.4, 
38.7, 37.6, 31.0, 28.1, 28.0, 23.4; m/z (ESI+) found [M+H]+ 545.2863, C29H41N2O8 















yl)carbamoyl)oxy)cyclopent-2-en-1-yl) pyrrolidine-1,2-dicarboxylate (3.9.23) 
Yield 46%; Rf = 0.5 (30% EtOAc/hexanes); IR (neat) 1744, 1714, 1693 cm-1; 1H NMR 
(400 MHz, CDCl3) 6.24 – 5.95 (m, 2H), 5.89 – 5.63 (m, 2H), 5.22 (d, J = 8.1 Hz, 1H), 
4.32 – 3.97 (m, 2H), 3.64 – 3.27 (m, 2H), 2.50 – 1.62 (m, 10H), 1.45 (s, 9H), 1.43 (s, 
9H), 1.40 (s, 9H); 13C NMR (101 MHz, CDCl3) 13C NMR (101 MHz, CDCl3) δ 172.2, 
171.9, 171.2, 155.9, 154.8, 154.4, 136.3, 136.2, 135.4, 135.1, 82.4, 81.4, 81.2, 80.8, 79.2, 
79.1, 60.0, 59.6, 54.0, 46.9, 46.5, 37.8, 31.6, 31.0, 30.0, 28.2, 28.1, 28.1, 24.3, 23.5; m/z 









(3.9.25). Yield 49%; Rf = 0.3 (30% EtOAc/hexanes); IR (neat) 1744, 1690 cm-1; 1H NMR 
(400 MHz, CDCl3) 7.34 – 7.20 (m, 3H), 7.20 - 7.13 (m, 2H), 6.15 – 5.89 (m, 2H), 5.57 – 

















7.5 Hz, 2H), 2.92 – 2.74 (m, 1H), 1.74 (m, 1H), 1.46 (s, 9H), 1.39 (s, 9H), 1.36 (d, J = 7.2 
Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 172.3, 170.7, 155.7, 155.4, 136.2, 134.8, 129.6, 
128.5, 127.1, 119.2, 82.4, 82.1, 78.2, 55.3, 50.2, 39.2, 38.7, 37.6, 28.3, 28.1, 19.1; m/z 









(3.9.28). Yield 60%; Rf = 0.2 (30% EtOAc/hexanes); IR (neat) 1747, 1705 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 6.09 (d, J = 8.3 Hz, 2H), 5.50 (dt, J = 7.6, 4.0 Hz, 2H), 5.28 (dd, J = 
23.0, 7.9 Hz, 1H), 4.57–4.16 (m, 2H), 3.93 (p, J = 6.9 Hz, 1H), 2.84 (dt, J = 15.0, 7.5 Hz, 
1H), 2.52 (m, 2H), 2.20–2.05 (m, 4H), 1.95 (m, 1H), 1.76 (dt, J = 14.8, 3.8 Hz, 1H), 1.47 
(s, 9H), 1.46 (s, 9H), 1.37 (d, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 170.97, 
170.95, 155.5, 155.2, 134.7, 134.6, 82.4, 81.9, 53.7, 53.5, 50.1, 46.2, 37.4, 32.5, 29.9, 
28.0, 27.9, 18.9, 15.5; m/z (ESI+) found [M+H]+ 503.2427, C23H39N2O8 requires 















Yield 60%; Rf = 0.3 (30% EtOAc/hexanes); IR (neat) 1746, 1700 cm-1; 1H NMR (400 
MHz, CDCl3) δ 6.05 (m, 2H), 5.58–5.38 (m, 2H), 5.36–5.00 (m, 2H), 4.34–4.03 (m, 2H), 
2.85 (dt, J = 15.0, 7.6 Hz, 1H), 2.45–2.04 (m, 3H), 2.01–1.69 (m, 2H), 1.49 (s, 9H), 1.48 
(s, 9H), 1.46 (s, 9H), 1.38 (d, J = 7.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 172.1, 
172.0, 171.2, 155.7, 155.3, 134.9, 134.8, 82.4, 82.0, 80.8, 79.1, 54.0, 50.2, 41.1, 40.3, 
37.5, 31.6, 28.2, 28.13, 28.10, 19.0; m/z (ESI+) found [M+H]+ 557.3070, C27H45N2O10 








butoxy)phenyl)propanoate 3.9.7). Yield 59%; Rf = 0.2 (30% EtOAc/hexanes); IR (neat) 
1749, 1705 cm-1; 1H NMR (400 MHz, CDCl3) δ 8.07 (s, 1H), 7.58 (d, J = 7.9 Hz, 1H), 
7.48–6.91 (m, 9H), 6.07 (s, 2H), 5.72 (s, 2H), 5.13 (dd, J = 31.1, 8.2 Hz, 2H), 4.70–4.26 
(m, 2H), 3.45–3.13 (m, 2H), 3.06 (d, J = 6.2 Hz, 2H), 2.36–1.90 (m, 2H), 1.40 (s, 9H), 



















128.5, 127.9, 127.0, 122.7, 122.3, 119.6, 119.1, 111.2, 110.6; 110.4, 82.4, 82.1, 79.1, 
78.9, 60.5, 55.3, 53.5, 38.6, 37.9, 28.1, 21.1, 14.3; m/z (ESI+) found [M+H]+ 634.3125, 








(3.9.25). Yield 52%; Rf = 0.3 (30% EtOAc/hexanes); IR (neat) 1747, 1703 cm-1; 1H NMR 
(400 MHz, CDCl3) δ7.36–7.07 (m, 5H), 6.22–6.00 (m, 2H), 5.85–5.59 (m, 2H), 5.26–
4.90 (m, 2H), 4.68–4.57 (m, 1H), 4.34–3.95 (m, 1H), 3.19–2.82 (m, 2H), 2.35–1.89 (m, 
2H), 1.46 (s, 9H), 1.39 (s, 9H), 1.35 (d, J = 7.2 Hz, 3H); 13C NMR (101 MHz, CDCl3) 
δ171.5, 172.3, 170.7, 136.2, 135.7, 129.7, 129.6, 128.5, 128.4, 127.1, 126.8, 82.4, 79.1, 
78.9, 55.2, 54.6, 38.9, 38.6, 37.6. 28.10, 28.08; (m/z (ESI+) found [M+H]+ 519.2706, 






(1S,3S)-Cyclopent-4-ene-1,3-diol (S,S-3.13.2). A solution of (3S,5S)-hepta-1,6-diene-
3,5-diol (500 mg, 3.91 mmol) in DCM (78 mL) and methanol (78 mL) was purged with 
argon for 15 min and 5 mol% of Grubbs II catalyst (166 mg) was added to it. The 
reaction mixture was stirred at rt for 6 h and was quenched with DMSO (1 mL). The 












purified by silica gel chromatography (100% EtOAc) to afford the product as colorless 
oil (266 mg, 68%). Rf = 0.20 (100% EtOAc); IR (neat) 3420 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 6.05–6.01 (m, 2H), 5.07 (t, J = 4.8 Hz, 2H), 2.10 (t, J = 5.0 Hz, 2H), 1.56 (br s, 
2H); 13C NMR (101 MHz, CDCl3) δ 137.4, 76.4, 44.4; m/z (ESI+) found [M+Na]+ 
123.0421, C5H8NaO2 requires 123.0422; [!]!!".! –232 (c 1.0, MeOH).   
 
 




On a 6x4-well heating block, 24 two-dram vials were placed. Each of the C2-symmetric 
diols (30 mg) was charged separately into 6 two-dram vials. Then amino acid isocyanate 
(3 eq) were charged and 10% N,N’-DMAP were added. To each vial 0.1 mL of THF was 
added to facilitate the mixing of the reagents. The vials were closed with Teflon caps and 
the block was heated to 100 ºC for 2 h. Following cooling 2 mL of dichloromethane was 
added to each vial. The contents of the vials were transferred to 24 different collection 
tubes. The solvent was evaporated by purging nitrogen gas to obtain the crude reaction 

























X = CH2, (S,S)-2.16.3
X = NCH2Ph  (S,S)-2.18.3

















was purified by column chromatography to obtain the products 25–35 mg of quantity (the 
spectral data is listed below). The rest of the crude library compounds were subjected to 
mass-directed purification and analysis, however due to lack of an analytical response the 







diylbis(oxy))bis(carbonyl))bis(azanediyl))bis(3-phenylpropanoate (3.14.1). Yield 
66%; Rf = 0.3 (30% EtOAc/hexanes); IR (neat), 1744, 1693 cm-1; 1H NMR (400 MHz, 
CDCl3) δ7.37–7.05 (m, 10H), 6.07–5.97 (m, 2H), 5.79–5.64 (m, 2H), 5.18 (m, 2H), 4.51–
4.21 (m, 2H), 3.16–2.86 (m, 4H), 2.17 (t, J = 5.1 Hz, 2H), 1.41 (s, 18H); 13C NMR (101 
MHz, CDCl3) δ170.6, 155.5, 136.2, 135.6, 129.5, 128.5, 127.1, 82.3, 79.0, 55.2, 38.6, 
37.8, 28.0; (m/z (ESI+) found [M+H]+ 595.3018, C33H43N2O8 requires 595.3019; [!]!!".! 







diylbis(oxy))bis(carbonyl))bis(azanediyl))bis(3-phenylpropanoate) (3.14.7). Yield 










CDCl3) δ7.62–6.81 (m, 10H), 5.36–4.82 (m, 2H), 4.73–4.23 (m, 4H), 3.25–2.80 (m, 4H), 
2.36–2.13 (m, 2H), 2.05–1.84 (m, J = 5.9, 1H), 1.39 (s, 18H), 1.62–0.95 (m, 5H); 13C 
NMR (101 MHz, CDCl3) δ 170.7, 155.0, 136.2, 129.5, 128.4, 126.9, 82.2, 71.2, 55.0, 
38.4, 31.1, 27.9, 20.0; m/z (ESI+) found [M+H]+ 611.3330, C34H47N2O8 requires 








Yield 51%; Rf = 0.3 (50% EtOAc/hexanes); IR (neat) 1744, 1700 cm-1; 1H NMR (400 
MHz, CDCl3) δ7.36–6.90 (m, 15H), 5.22–5.02 (m, 3H), 4.54–4.20 (m, 2H), 3.62–3.37 
(m, 2H), 2.97 (d, J = 6.1 Hz, 4H), 2.62–2.46 (m, 2H), 2.42–2.24 (m, 2H), 1.84–1.52 (m, 
3H), 1.31 (m, 18H); 13C NMR (101 MHz, CDCl3) δ 170.6, 155.1, 137.4, 136.3, 129.6, 
129.1, 128.5, 128.4, 127.3, 127.0, 82.3, 68.5, 62.3, 56.1, 55.3, 38.7, 34.5, 28.0; m/z 



















Yield 57%; Rf = 0.4 (50% EtOAc/hexanes); IR (neat) 1747, 1697 cm-1; 1H NMR (400 
MHz, CDCl3) δ7.32–7.11 (m, 10H), 5.30–4.93 (m, 4H), 4.55–4.33 (m, 2H), 3.16–2.91 
(m, 4H), 2.78–2.65 (m, 2H), 2.59–2.48 (m, 2H), 1.87–1.68 (m, 2H), 1.40 (s, 18H); 13C 
NMR (101 MHz, CDCl3) δ170.5, 154.7, 136.2, 129.6, 128.5, 127.1, 82.4, 69.1, 55.3, 
38.7, 36.0. 31.6, 28.1; (m/z (ESI+) found [M+H]+ 629.2899, C33H45N2O8S requires 








Yield 59%; Rf = 0.3 (50% EtOAc/hexanes); IR (neat) 1744, 1698 cm-1; 1H NMR (400 
MHz, CDCl3) 5.41–4.89 (m, 4H), 4.33– 4.20 (m, 2H), 2.77 (dd, J = 13.5 Hz, 2.5 Hz, 2 
H), 2.68–2.53 (m, 2H), 2.19–1.76 (m, 2H), 1.46 (s, 18 H), 1.37 (d, J = 7.1 Hz, 6H); 13C 
NMR   (101 MHz, CDCl3) δ 172.0, 154.6, 81.9, 68.9, 50.1, 36.0, 31.6, 27.9, 18.8; m/z 
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